Means and methods for safe and efficient gene editing in cells

Abstract

The invention is directed to means and methods for efficient and safe genetic manipulation of a target cell, wherein a knock-out / knock in strategy is performed via HDR in a target gene that is haploinsufficient (and / or in single copy) in the cell.

Description

[0001]ADV-00738PTEPWO MEANS AND METHODS FOR SAFE AND EFFICIENT GENE EDITING IN CELLS FIELD OF THE INVENTION The present invention relates to means and methods for improving safety and efficiency of ex vivo or in vitro genetic manipulation of a cell. BACKGROUND Gene therapy by integrating viral vectors have achieved excellent safety and efficacy results in clinical studies for the treatment of several inherited diseases, both hematological and non- hematological. Yet, the use of semi-randomly integrating vectors still poses the risk of insertional mutagenesis, particularly when the viral vector bears highly active promoter / enhancer sequences15, and of non-physiological transgene expression. Targeted integration of a therapeutic sequence in a pre-defined locus of interest may allow to overcome this limitation, and this can be achieved by gene editing (GE) through homology- directed repair (HDR), which relies on the use of artificial nucleases for precise modification of endogenous genes. However, the application of GE by HDR, particularly in HSPCs, is currently constrained by low efficiency1,2of GE and potential genotoxicity10-12. Low efficiency of GE is mainly due to the relative quiescent state of the most primitive and long-term repopulating HSPCs which makes them not very permissive to HDR, given the low proportion of cells in the S / G2 phases of the cell cycle at the time of editing. Despite significant improvements have been obtained with different strategies3–5, current editing efficiency remains suboptimal, achieving on average 10-20% of gene marking in long-term engrafting HSPCs6–8. These levels of gene correction have been predicted to be safe and effective for the treatment of some diseases, such as in the case of X-linked Severe Combined Immunodeficiency (SCID-X1), in which the edited progeny would benefit of selective advantage over non-edited counterpart9. However, for other clinical applications, especially in conditions in which a higher threshold of edited cells is necessary for the correction of the pathological phenotype, it is crucial to improve the efficiency of gene editing as well as the yield of edited cells. This is even more relevant in gene editing of stem cells, such as HSPCs, for which it is essential to improve efficiency of gene editing in more primitive HSPCs. GE per se can be a source of potentially genotoxic events in cells10-12, both by gene disruption or HDR template integration at nuclease off-target sites and by loss of genetic material at the ADV-00738PTEPWO nuclease intended target site upon non-homologous (NHEJ) -mediated repair (e.g., long-range deletions and chromothripsis). Selection strategies are promising methods to increase efficiency and safety at the same time: as for efficacy, by providing an increase in the proportion of the cells bearing the intended edit; as for safety, by purging out cells bearing imprecise and potentially genotoxic DNA repair outcomes, such as indels, large deletions and chromosomal translocations. An approach for enrichment of HDR-edited HSPCs by “positive selection” (SMArT platforms): has been studied and validated by the present inventors (WO2020074729A1): this may be done by coupling the intended on-target editing outcome to transient expression of: a) cell-surface clinically compatible reporters that could allow for an ex vivo selection before transplantation; or b) biological selectors, i.e., molecules providing transient growth or engraftment advantage to the expressing cells, such as CXCR4, c-KIT, ITGA4. Others have also developed an approach for enrichment of HDR-edited cells by “negative selection”13, providing growth, homing or engraftment disadvantage to cells not bearing the intended on-target editing outcome: in this case, the selection (called SLEEK, SeLection by Essential-gene Knock-out) was obtained by knocking out essential genes (GAPDH, TBP and KIF11) to be reconstituted in the HDR cassette together with the gene of interest. This approach has proven effective in iPSCs, B cells, NK cells, T cells, but not HSPCs, in which it was used with the purpose of increasing the yield of immune cells genetically modified to express anti- tumoral soluble mediators. Although the SLEEK platform increases the efficacy of the final cell product, it is not assuring safety, since cells bearing indels are not counter-selected. Indeed, in the SLEEK approach positively selected cells can bear one allele faithfully repaired by HDR while having on the other an unwanted and potentially genotoxic editing outcome (e.g., large deletions or chromosomal translocations), as confirmed also by the authors of the SLEEK approach13. Safety and preservation of genome integrity is however extremely important for gene therapy, especially for gene therapy involving HSPCs, since gene edited cells have to last life-long and potentially repopulate the haematopoietic system of the recipient and may otherwise accumulate mutations triggering / promoting cell transformation. The limitations of the prior art are overcome by the present invention, aimed at providing a negative selection strategy wherein cells carrying undesired gene editing outcomes at the target site (e.g. large deletions, translocations, duplications, indels) are spontaneously purged out (in vitro and mainly in vivo), with consequent indirect advantage to cells that are HDR-edited. ADV-00738PTEPWO Moreover, this invention allows for more uniform editing outcomes and characterization of the transcriptional profile of strong promoters integrated into the target locus. BRIEF DESCRIPTION OF THE INVENTION The scope is achieved by the means and methods of the invention for efficient and safe genetic manipulation of a target cell, wherein a knock-out / knock in strategy is performed via HDR in a target gene that is haploinsufficient (and / or in single copy) in the cell. In particular, the invention is directed to means and methods for in vitro or ex vivo engineering of cells (target cells), preferably of stem cells or T cells, more preferably of hematopoietic stem cells (HSCs) and / or of hematopoietic stem and progenitor cells (HSPCs), via targeted integration by HDR gene editing of an exogenous knock-in cassette for expressing a gene of interest in a target site that is located in a functional region of a gene that is haploinsufficient (and / or in single copy) in the target cell, wherein a functional region of the haploinsufficient gene, that is disrupted by gene editing cutting, is reconstituted upon integration of the knock-in cassette. “Haploinsufficiency” in genetics describes a model of dominant gene action in diploid organisms, in which a single copy of the wild-type allele at a locus, even in heterozygous combination with a variant allele, is insufficient to produce the wild-type phenotype. Often, knock-out by NHEJ of one of two alleles of a gene is not detrimental to the cell, as one copy of the gene is sufficient for the cell to survive and function properly. Differently, in the case of haploinsufficient genes (i.e. genes for which two copies are required for proper function of the cell and / or genes that are present in single copy in the genome, such as X-linked genes in male somatic cells), their knockout or disruption by NHEJ results detrimental to the cell. In the latter scenario, NHEJ in HSPCs may lead to drastic impairments in the survival, engraftment, homing, and / or self-renewing of cells, which may also eventually die. Therefore, among the target cells undergoing gene editing in a haploinsufficient gene, according to the invention, those bearing biallelic or monoallelic knockout of the target genes, including those carrying aberrant repair events at the target site, such as long-range deletions or chromothripsis, are spontaneously purged out and counter-selected (Fig.1 A and B). Conversely, those bearing biallelic HDR-mediated integration (or monoallelic in the case of X- linked genes in males) of a template reconstituting the target gene open reading frame, simultaneously carrying the knock-in cassette for expressing the gene of interest, preserve their biological functions and are enriched (Fig.1 C and D). ADV-00738PTEPWO The present invention is then directed to a method for in vitro or ex vivo engineering of a cell, comprising introducing into a cell: a) a gene editing agent comprising, or consisting of: a.i) a nuclease capable of introducing a double strand break (DSB) in a target site in the cell genome; and a.ii) a guide RNA (gRNA) targeting the target site; wherein the target site is located within a functional region of a target gene, wherein the target gene is a gene that is haploinsufficient and / or that is present in single copy in the cell; and b) a donor template that comprises: b.i) a knock-in cassette comprising an exogenous polynucleotide encoding a gene product of interest, or a portion thereof; and b.ii) homology arms (HAs) on either side of the knock-in cassette, wherein the 5' homology arm (or “left” homology arm) has a sequence that is homologous (e.g. identical) to a sequence located 5' of the DSB in the target site of the cell genome and the 3' homology arm (“right” homology arm) has a sequence that is homologous to a sequence located 3' of the DSB in the target site of the cell genome; wherein the donor template comprises an exogenous polynucleotide having sequence capable of reconstituting the target gene upon integration of the knock-in cassette into the target site of the cell by homology-directed repair (HDR) of the DSB, such that integration of the knock-in cassette by HDR of the DSB results in a gene edited cell that expresses the gene product of the target gene and the gene product of interest. In some embodiments, the DSB is achieved by using a double-nick approach: double nick approach in CRISPR-Cas9 genome editing uses two separate guide RNAs to direct a nickase (a Cas9 nuclease with a modified catalytic domain) to create a single-strand break (nick) in each strand of the target DNA. Therefore, in some embodiments the gene editing agent comprises a.i.1) a nickases capable of introducing a single strand break (nick) in a strand of the target site in the cell genome, and a.ii.2) a pair of guide RNA (gRNA) each targeting the nickase to opposite strands of the target site. These double nicks create a double-strand break (DSB). Advantageously, double-nick approaches combine efficient editing with greatly reduced off- target effects17. With “reconstituting the target gene” it is meant reconstituting the functionality of the target gene. For instance, the polynucleotide reconstituting the target gene can reconstitute the open ADV-00738PTEPWO reading frame of the target gene and / or restore the function of a regulatory element of the target gene, such as a splicing site, or of any other element of the gene that regulates expression of the gene product, that was disrupted by the DSB. Optionally, reconstitution of the target gene can include reconstitution of the target gene sequence; however, in accordance with the present invention, when exogenous sequences corresponding to endogenous sequences of the target gene are introduced by HDR in the DSB, said exogenous sequences are preferably codon-usage optimized sequences. Therefore, the gene product of the target gene that is reconstituted in the gene edited cell is encoded by a sequence that is homologous but not identical to the endogenous sequence. According to the method of the invention, when the knock-in cassette is not integrated into the target site of the cell by homology-directed repair (HDR), in the correct position or orientation, the cell no longer expresses the gene product encoded by the target gene and it is therefore spontaneously purged out (in vitro and mainly in vivo), with consequent indirect advantage to cells that are HDR-edited. The invention is also directed to a kit for in vitro or ex vivo engineering of a cell, comprising: a) a gene editing agent comprising, or consisting of: a.i) a nuclease capable of introducing a double strand break (DSB) in a target site in the cell genome; and a.ii) a guide RNA (gRNA) targeting the target site; wherein the target site is located within a functional region of a target gene, wherein the target gene is a gene that is haploinsufficient and / or that is present in single copy in the cell; and b) a donor template that comprises: b.i) a knock-in cassette comprising an exogenous polynucleotide encoding a gene product of interest, or a portion thereof; and b.ii) homology arms (HAs) on either side of the knock-in cassette, wherein the 5' homology arm (or “left” homology arm) has a sequence that is homologous (e.g. identical) to a sequence located 5' of the DSB in the target site of the cell genome and the 3' homology arm (“right” homology arm) has a sequence that is homologous to a sequence located 3' of the DSB in the target site of the cell genome; wherein the donor template comprises an exogenous polynucleotide having sequence capable of reconstituting the target gene, upon integration of the knock-in cassette into the target site of the cell by homology-directed repair (HDR) of the DSB, ADV-00738PTEPWO such that integration of the knock-in cassette by HDR of the DSB results in a gene edited cell that expresses the gene product of the target gene and the gene product of interest; the kit optionally comprising c) a cell population. In alternative embodiments, the above-described kit for in vitro or ex vivo engineering of a cell, instead of a.i) a nuclease capable of introducing a double strand break (DSB), comprises: a.i.1) a nickase capable of introducing a single strand break in a DNA strand of the target site and comprises a.ii.2) a pair of guide RNA (gRNA), each targeting the nickase to opposite strands of the target site. Further, the present invention is directed to a gene edited cell, obtainable by the method of the invention, and to pharmaceutical formulations comprising a population of the gene edited cells and suitable pharmaceutically acceptable excipients. Said gene edited cell integrates in the target site of the target gene the knock-in cassette for expressing the gene of interest. Said cell expresses both the gene product of the target gene and the gene product of interest. In a further aspect, the present invention is also directed to the kit or to the gene edited cell obtainable by the method of the invention, or the pharmaceutical formulation thereof, for use as a medicament, preferably for use in the treatment of a genetic disease, that can be treated by expressing the gene product of interest in a cell (gene therapy). The present invention is then also directed to the kit or to the gene edited cell obtainable by the method of the invention, or the pharmaceutical formulation thereof, for use as medicament in gene therapy, preferably in ex vivo gene therapy. The present invention is directed also to a method of treatment of a genetic disease comprising administering to a subject in need thereof a therapeutic amount of the kit, or gene edited cells of the invention, or pharmaceutical formulations thereof. The invention is best understood from the following detailed description, when read in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF FIGURES Fig.1 Schematic representation of the selection strategy according to the invention. A. schematic representation of a break (vertical line) operated by a gene editing agent in a target site of a functional region (exon N) of a target gene B. schematic representation of unwanted dysfunctional repair mechanisms, occurring after disruption of the target gene, such as (i) NHEJ (i), putting the disrupted exon N out of frame or producing genotoxic secondary byproducts with indels, (ii) long range deletions, and / or (iii) translocation, resulting fatal to the target cell and / or its progeny (negative selection). C. schematic representation of the elements of the kit for gene editing of the invention including a gene editing agent targeting a target site in exon N ADV-00738PTEPWO of a target gene and a donor template comprising a knock in cassette for integration by HDR in the target, expressing the disrupted exon N and a gene of interest (GOI) under a promoter, in between the homology arms (HA). D. schematic representation of the integration of the knock in cassette in the genome of the gene edited cell, resulting in repaired cell that is able to survive and engraft long-term. Fig.2. Screening of candidate target genes in vitro. A. scheme of the experimental design of Example 1 for selecting preferred target genes in HSPCs B. Results of editing efficiency expressed as the percentage of indels present in the bulk culture of HSPCs, measured 4 days after editing, for each gene and each gRNA tested, represented in the graph by each bar, compared to control condition. C. Results of clonogenic assay expressed as the number of red and white colonies counted for each gene and each guide gRNA tested, represented in the graph by each bar, 14 days after editing. Absolute number of colonies are counted and compared to the control condition (dotted line). Results are shown as median values. The arrows point the guide RNAs that were most effective in impairing colonies in vitro. Fig.3. In vivo engraftment and indels’ purge out in xenograft models of edited HSPCs A. scheme of the experimental design of Example 2 B. Human cells engraftment evaluated as percentage of cells staining positively for the surface antigen human CD45 at FACS. Results are shown for cells edited with gene editing agents knocking out (KO) UBA1 gene (on the left), RPS19 gene (in the middle) and AIFM1, DKC1 and OGT genes (on the right). For RPS19 two gRNAs were tested, gRNA 1 and 3, respectively disrupting exon 5 and 4 (RPS191 KO and RPS193 KO in the graph) C. Percentage of indels in the human graft, expressed in terms of fold growth, obtained when normalizing for in vitro editing efficiency where 1 is the fold growth at the moment of transplantation (input). Final graft fold is evaluated in blood, spleen (SPL) and bone marrow (BM) at week 13, for UBA1 gene (on the left), RPS19 gene (in the middle) and OGT, DKC1 and AIFM1 genes (on the right). Gene editing in genomic safe harbor AAVS1 is taken as control. Fig.4. HDR strategy in UBA1 and RPS19 loci. A. scheme of the insertion in UBA1 gene of the knock-in cassettes prepared in Example 3: in the upper part of the figure the native structure of UBA1 gene is shown, with exons (boxes numbered from 1 to 25), introns (light line) and 3’ UTR region (right arrow); at the end of exon 3 a vertical arrow with scissors shows the target site that is cut by the gene editing agent, wherein a knock-in cassette is inserted as transgene by HDR. In the lower part of the figure it is shown the knock-in cassette inserted as transgene in the target site by HDR (homology arms ADV-00738PTEPWO are not shown); the knock-in cassette (sense) includes from the 5’ end to the 3’ end: the final portion of exon 3 of UBA1 gene which is codon-usage optimized (recoded), a splicing donor domain (SD) and the cassette for expressing a gene of interest, consisting of a strong viral promoter (Spleen Focus-Forming Virus promoter, SFFV), enhanced green fluorescent protein (EGFP, mocking the gene of interest) and a bovine growth hormone (bGH) polyadenylation domain (polyA); an antisense cassette is also shown, wherein the cassette for expressing the gene of interest is in antisense direction as compared to the native gene. B. scheme of the insertion in RPS19 gene of the knock-in cassettes cassette prepared in Example 3: in the upper part of the figure the native structure of RPS19 gene is shown, with exons (boxes numbered from 1 to 6), introns (light line) and 3’ UTR region (right arrow); at the end of exon 5 a vertical arrow with scissors shows the target site that is cut by the gene editing agent, wherein a knock- in cassette is inserted as transgene by HDR. In the lower part of the figure it is shown the knock- in cassette inserted in the target site by HDR (homology arms are not shown); the knock-in cassette includes from the 5’ end to the 3’ end: the final portion of the coding sequence (CDS) of exon 5, codon-usage optimized, and the CDS of exon 6, a P2A domain (encoding for self- cleaving peptide 2A) for ribosomal skipping in translation, and the cassette for expressing a gene of interest with EGFP (mocking the gene of interest), that is under the control of the endogenous promoter of the RPS19 gene, followed by a bGH polyA domain. Fig.5. clonogenic assay of HDR-edited HSPCs in UBA1 and RPS19 loci. A. scheme of the experimental design of Example 4 for evaluating the efficacy of the method of the invention when targeting UBA1 and RPS19 loci. B. Results for UBA1 locus: left graph shows the HDR efficiencies by FACS in the HDR-edited groups (with sense and anti-sense construct respectively); middle graph shows the absolute number of red and white colonies in each group; right graph shows the percentage of GFP positive cells among the colonies for HDR-edited groups. C. Results for RPS19 locus: left graph shows the HDR efficiencies by FACS in the HDR-edited groups (with sense and anti-sense construct respectively); middle graph shows the absolute number of red and white colonies in each group (RNP= KO only condition, AAV=AAV vector without RNP delivery, HDR=full HDR condition, UT=untreated; right graph shows the percentage of GFP positive cells among the colonies for HDR-edited groups. Fig.6. in vivo engraftment of HDR-edited HSPCs in UBA1 locus. A. scheme of the experimental design of Example 5 for evaluating the efficiency of in vivo engraftment of HDR-edited HSPCs in UBA1 locus. For each group of treatment (AAVS1, UBA1 sense and antisense constructs) there was an RNP only group (KO) and a full HDR group.30 ADV-00738PTEPWO NBSGW female mice (6 per group) were used, without need for irradiation prior to transplantation. B. human engraftment at sacrifice (13 weeks after transplantation) measured as percentage of hCD45 positive cells in mice’s peripheral blood (left), spleen (middle) and bone marrow (right). C. HDR efficiency, measured as percentage of edited alleles (in vitro, figure on the left) evaluated 4 days after editing as average edited copies per cell in each HDR-edited condition, and as percentage of GFP expression (in vivo, figure on the right) within human cells, respectively, from left to right, in the peripheral blood, spleen and bone marrow, 13 weeks after transplantation. Fig.7 further HDR strategies in RPS19 and OGT loci A. scheme of the alternative knock-in cassette insertion in RPS19 locus prepared in Example 6: as compared to that shown in Fig.4B, in the alternative cassette bGH polyA domain is missing; a splicing donor (SD) domain, provided through the right homology arm, keeps the 3’UTR of RPS19 in frame. B. scheme of the insertion in OGT gene of the alternative knock-in cassette prepared in Example 6, including from the 5’ end to the 3’ end the final portion of exon 3 of UBA1 gene (sense) which is codon-usage optimized (recoded), a splicing donor domain (SD) and the cassette for expressing a gene of interest (antisense with respect to native gene), consisting of a SFFV promoter, EGFP and bGH polyadenylation domain (polyA). C. scheme of the insertion inside the first intronic region of PPP1R12C gene in the control locus (AAVS1) of the knock-in cassette prepared in Example 6, including from the 5’ end to the 3’ end, in antisense direction with respect to PPP1R12C gene, a SFFV promoter, EGFP and bGH polyA (homology arms are not shown). Fig.8 clonogenic assay of HDR-edited HSPCs in UBA1, RPS19 and OGT loci A. absolute number of colonies (CFU) in mock edited condition (Mock), in AAVS1 control groups knock-out and HDR (AAVS1 K.O. and AAVS1-SFFV), and for the target loci UBA1, OGT, and RPS19 exon 5, in the RNP-only groups (UBA1 K.O., OGT K.O., RPS19 ex5 K.O.) and in their HDR-edited counterparts (UBA1 SFFV, OGT SFFV, RPS19 ex5-P2A-3’UTR and RPS19 ex5-P2A-bGH). B. percentage of GFP expressing cells (GFP+) measured at FACS level first in the vitro culture (CD90+ cells) at day 4 and 7 after editing (columns D4 and D7) and then in the CFUs at day 14 after editing (D14(CFA)) within the indicated loci. C. Median Fluorescence Intensity (MFI) of GFP in GFP expressing cells (GFP+), measured by FACS analysis on the bulk vitro culture cells (day 7 after editing) and plotted in terms of ratio over GFP- cells in the same sample. D. % of GFP+ cells within the CD90+ compartment of cord- blood derived HSPCs culture at days 4 (D4) and 7 (D7) and within the CFU-derived cells, ADV-00738PTEPWO edited in AAVS1, UBA1 and OGT loci. E. absolute number of colonies in AAVS1, UBA1 and OGT loci, for knock-out (K.O.) and HDR groups. Fig.9 in vivo engraftment of HSPCs HDR-edited in OGT and RPS19 loci A. human engraftment at sacrifice (13 weeks after transplantation) measured as percentage of hCD45+ cells in sub-lethally irradiated NSG mice’s (left), in peripheral blood (PB), spleen (SPL) and bone marrow (BM). B. HDR efficiency, measured as percentage of edited alleles in vitro evaluated 7 days after editing as average edited copies (% of GFP+ cells at FACS in the CD90+ compartment) in each HDR-edited condition, and as percentage of GFP expression in vivo within human CD45+ cells in PB, SPL and BM. C. human engraftment measured throughout the whole experiment as percentage of hCD45 positive cells in mice’s PB, SPL, and BM. D. HDR efficiency, measured as percentage of edited alleles in vitro evaluated 7 days after editing as % of GFP+ cells at FACS in the CD90+ compartment, and as percentage of GFP expression (in vivo) within CD45+ human cells, in PB, SPL and BM, at 7 days after editing. E. human engraftment measured throughout the whole experiment as percentage of hCD45 positive cells in mice’s PB, SPL, and BM, using female donor’s HSPCs as source. F. HDR efficiency, measured as percentage of edited alleles in vitro evaluated 7 days after editing as % of GFP+ cells at FACS in the CD90+ compartment, and as percentage of GFP expression (in vivo) within CD45+ human cells, in PB, SPL and BM, at 7 days after editing. G. scheme of the experimental design for evaluating the efficiency of in vivo engraftment of HDR-edited HSPCs in UBA1 locus, with different days of editing as compared to that of thawing of HSPCs: day minus 3 (D3) was compared to shorter pre-stimulation culture conditions at days minus 2 (D2) and minus 1 (D1). H. HDR efficiency, measured as percentage of edited alleles in vitro evaluated 7 days after editing as % of GFP+ cells at FACS in the CD90+ compartment, and as percentage of GFP expression (in vivo) within CD45+ human cells, in PB, SPL and BM, at 7 days after editing. Results are shown in terms of human engraftment (and %GFP+ cells within the human cells. Fig.10 efficiency and safety of selection strategy A. HDR efficiency on each locus measured on samples of 4 biological replicates both in culture cells (day 1, 4 and 7 after editing) and in formed colonies (14 days after plating the colonies). The results are shown as the copy number (CN) over a normalizer (TTC5) in time. In X-linked genes analysis (lower graph) results in AAVS1 locus are normalized for being bi-allelic, in order for proper comparation with OGT and UBA1, which are monoallelic. B. comparison of the results of nanopore sequencing on colonies derived from HSPCs edited at UBA1 target locus vs control region counterpart (AAVS1). Some sequencing artifacts and wild type reads are ADV-00738PTEPWO present in both samples. “Clean HDR” according to the present invention is instead much more abundant in UBA1 condition as compared to AAVS1 condition, which displays also trapping, small deletions, concatemers. C. Results of ddPCR deletion assays on HDR-edited colonies in control locus (AAVS1) and in haploinsufficient target loci (UBA1, OGT, RPS19). For each locus results are displayed evaluating either upstream or downstream to the integration cassette both on colonies derived from HDR-edited HSCPs and on colonies derived from mock-edited HSCPs from the same biological donor. The lowest values in terms of expression of the evaluated region as compared to a normalizer (Telo) in mock-derived colonies is identified as the lower threshold (dotted line) for absence of genomic region (i.e. droplets under this threshold in the HDR-derived colonies are considered negative for the genomic region tested). D. Results of in vitro gene expression studies through ddPCR on cDNA derived from sorted GFP+ cells as compared to sorted GFP- cells at the end of culture (w / in CD34+ alive cells) over the expression of a normalizer (HPRT1 gene). In each case the expression of the evaluated genes in the target loci-edited samples was compared to the one in HDR-edited samples in AAVS1 locus and to a mock edited sample (in the legend + means GFP positive and – means GFP minus). Fig.11 Assessment of further candidate haploinsufficient genes Number of colonies formed by HSPCs edited in the indicated tested genes. Fig.12 Efficiency of the selection strategy in T cells. A. experimental design. B. % of GFP positive T cells in culture measured by FACS on days 4, 7 and 10 after editing. C. vitality of cells in culture in all conditions (labels of condition on X axis) during culture (Y axis displays the days after editing). D. fold growth of cells in culture during post-editing culture: Y axis represents the theoretical number of cells in culture (i.e. real counts corrected for number of cells used at each time point for FACS and pellets); X axis represents the days after editing. Each graph reports both the studied locus (with RNP and HDR conditions) and the same conditions in AAVS1 locus as control. Fig.13 Proof of concept of clinical application of the strategy of the invention A. ABCD1corrective cassette in UBA1 locus for the treatment of X-ALD as described in Example 14. B. vitality in culture of UBA1 KO and of the different corrective constructs of HSPCs after editing, as compared to AAVS1 KO and AAVS1 HDR conditions. C. HDR efficiency over time in the bulk culture (day 4, 7 and 10 after editing) and in colonies (14 days after plating) measured by ddPCR with UBA1-ABCD1 construct in UBA1 locus as compared to AAVS1 HDR (CN= copy number of HDR edited alleles). HDR efficiency in AAVS1 locus is normalized on the number of alleles. D. number of colonies (CFU) in clonogenic assay derived ADV-00738PTEPWO from HSPCs-edited cells in a mock condition, in AAVS1 (KO and HDR), and in UBA1 (KO and HDR, with EGFP and ABCD1 bearing constructs). E. expression levels of EGFP and the hyperexpression of ALP protein (ALPh), compared to that of EGFP in AAVS1 locus and that of ALPh in a vector only condition. DETAILED DESCRIPTION OF THE INVENTION Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of cells, such as a population of cells. The term “about” or “approximately” in relation to a numerical means, a range of values that fall within 10% greater than or less than the value. For example, about x means x± (10% * x). The terms “engineered” or “genetically modified” or “genetically manipulated”, as referred e.g. to cells, are herein used interchangeably. “Engineering” or “genetic modification” or “genetic manipulation” include “gene transfer”, “gene editing” and “epigenetic editing”. In the present invention, the terms “engineering” or “genetic modification”, referred to a cell or organism that is “engineered” or “genetically modified” mean “gene editing”. The term “gene transfer” " or "gene delivery" refers to the transfer of genetic material (e.g., DNA or RNA) of interest into a cell, typically to treat or prevent a genetic or acquired disease or condition. For instance, the term “gene transfer” " or "gene delivery" can refer to the addition of a copy of a gene into the genome of a cell, such as a correct copy of a gene that is completely or partially deleted, or completely or partially not functional, in a cell (gene therapy). In particular, the genetic material of interest typically encodes a product (e.g., a protein polypeptide, peptide or functional RNA) whose production in vivo is desired. For example, a genetic material of interest can encode a gene product that is an enzyme, hormone, receptor, or polypeptide of therapeutic value. "Gene transfer" or "gene delivery" also refer to methods or systems for reliably introducing DNA or RNA of interest into a host cell. Such methods can result in transient expression of non-integrated transferred DNA, extrachromosomal replication and expression of transferred replicons (e.g., episomes), or integration of transferred genetic material into the genomic DNA of host cells. The term “gene editing” refers to the modification of the genome of a cell at a specific location to correct or alter a genetic sequence. The term “gene editing” refers in particular to a type of genetic engineering in which a nucleic acid is inserted, deleted or replaced in a cell. In ADV-00738PTEPWO accordance with the present invention, the term “gene editing” encompasses targeted disruption of a gene coding sequence and precise sequence substitution for in situ and targeted transgene insertion into a predetermined locus in the genome of a cell. A “gene transfer agent” is an agent capable of transferring a gene into a cell, such as a transgene and / or a vector for delivering a transgene, such as a vector comprising a transgene. The term “gene editing agent” or “gene editor” refers to an agent capable of editing a target site in the genome of a cell, e.g. by mediating disruption of the target site and / or correcting the target site. In accordance with the present invention, a gene editing agent is preferably an agent capable of disrupting a target site in the genome of a cell. The term "vector" refers to a particle capable of delivering, and optionally expressing, one or more polynucleotides of interest into a host cell. Examples of vectors include, but are not limited to, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells. The vector can be a cloning vector, suitable for propagation and for obtaining polynucleotides, gene constructs or expression vectors incorporated to several heterologous organisms. A vector is capable of transferring nucleic acid sequences to target cells, therefore also viral vectors, non-viral vectors, particulate carriers, and liposomes are included in the term “vector”. Typically, "vector construct", "expression vector" and "gene transfer vector" mean any nucleic acid construct capable of directing the expression of a nucleic acid of interest and which can transfer nucleic acid sequences to target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors. The term “recombinant plasmid” or “plasmid” refers to a small, circular, double- stranded, self- replicating DNA molecule obtained through genetic engineering techniques capable of transferring genetic material of interest to a cell, which results in production of the product encoded by that said genetic material (e.g., a protein polypeptide, peptide or functional RNA) in the target cell. Furthermore, the term “recombinant plasmid” or “plasmid” also refers to a small, circular, double-stranded, self-replicating DNA molecule obtained through genetic engineering techniques used during the manufacturing of viral vectors as carriers of the recombinant vector genome. The term “recombinant viral vector” or “viral vector” refers to an agent obtained from a naturally occurring virus through genetic engineering techniques capable of transferring genetic material (e.g., DNA or RNA) of interest to a cell, which results in production of the product encoded by that said genetic material (e.g., a protein polypeptide, peptide or functional RNA) in the target cell. Herein, the terms “vector transgene" or “recombinant vector transgene" refer ADV-00738PTEPWO to a transgene that is transferred to the recipient cell upon transduction. The term “viral vector” or “recombinant viral vector”, as used herein, also refers to the recombinant viral particles being a packaged viral vector, capable of binding to and entering recipient cells, delivering the vector transgene. Viral delivery includes but is not limited to delivery by adenoviral vectors, adeno-associated viral (AAV) vectors, herpes viral vectors, retroviral vectors, lentiviral vectors, integrase- defective lentiviral vectors and baculoviral vectors. The terms “nucleotide sequence” or “isolated nucleotide sequence” or “polynucleotide sequence” or “polynucleotide” or “isolated polynucleotide sequence” are interchangeably used herein and refer to a nucleic acid molecule, either DNA or RNA, containing deoxyribonucleotides or ribonucleotides respectively. The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. The terms "variant" refers to biologically active derivatives of the reference molecule that retain desired activity. In general, the term "variant" refers to molecules having a native sequence and structure with one or more additions, substitutions (generally conservative in nature) and / or deletions, relative to the native molecule, so long as the modifications do not destroy biological activity, and which are "substantially homologous" to the reference molecule. In general, the sequences of such variants will have a high degree of sequence homology to the reference sequence, e.g., sequence homology of more than 50%, generally more than 60-70%, even more particularly 80-85% or more, such as at least 90-95% or more, when the two sequences are aligned. In accordance with the present invention, a variant of any biomolecule is a biomolecule that has a nucleic acid or aminoacidic sequence having a % of identity of 50%, 60%, 70%, 80%, 90%, 95%, or 99% to the wild-type nucleic acid or aminoacidic sequence and that retains the biological activity of the wild-type biomolecule. In preferred aspects, the term “variant” of a polynucleotide sequence is used herein to indicate serum-free sequence having a % of identity of at least 90%, 95% or 99% to said polynucleotide sequence. In preferred aspects, the term “variant” of a polynucleotide sequence is used herein to indicate a sequence that is a codon- optimized sequence for expressing the biomolecule encoded by said sequence. The terms “% sequence identity”, “% identity” or “% sequence homology” refer to the percentage of nucleotides or amino acids of a candidate sequence that are identical to the nucleotides or amino acids in the sequence of reference, after aligning the sequences to achieve the maximum % sequence identity. In a preferred embodiment, sequence identity is calculated based on the full length of two given sequences or on part thereof. The % sequence identity can be determined by any methods or algorithms established in the art, such as the ALIGN, BLAST ADV-00738PTEPWO and BLAST 2.0 algorithms and followings. Herein, the “% sequence identity”, “% identity” “or “% sequence homology” is calculated dividing the number of nucleotides or amino acids that are identical after aligning the sequence of reference and the candidate sequence, by the total number of nucleotides or amino acids in the sequence of reference and multiplying the result by 100. In accordance with degeneration of genetic code, variants include sequences where at least one base of the base sequence of a gene is replaced with a different type of base, without changing the amino acid sequence of the polypeptide expressed from the gene. Variants also include codon-optimized sequences and sequences comprising mutated or added nucleotides, e.g., for cloning needs. Codon optimization has previously been described in WO 1999 / 41397 and WO 2001 / 79518. Different cells differ in their usage of particular codons. This codon bias corresponds to a bias in the relative abundance of particular tRNAs in the cell type. By altering the codons in the sequence so that they are tailored to match with the relative abundance of corresponding tRNAs, it is possible to increase expression. By the same token, it is possible to decrease expression by deliberately choosing codons for which the corresponding tRNAs are known to be rare in the particular cell type. Thus, an additional degree of translational control is available. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms. Variants also include sequences encoding fragments of any biomolecule, i.e., a shorter form of the biomolecule, such as a truncated form, that retains the biological activity of the wild-type biomolecule. The terms “codify”, “coding” or “encoding” refer to the genetic code that determines how a nucleotide sequence is translated into a polypeptide or a protein. The order of the nucleotides in a sequence determines the order of amino acids along a polypeptide or a protein. The term "transcriptional regulatory region" or “regulatory element, or region”, as used herein, refers to a nucleic acid fragment capable of regulating the expression of one or more genes. The regulatory regions of a polynucleotides of the invention may include a promoter, plus response elements, activator and enhancer sequences for binding of transcription factors to aid RNA polymerase binding and promote expression, and operator or silencer sequences to which repressor proteins bind to block RNA polymerase attachment and prevent expression. The term "promoter" must be understood as a nucleic acid fragment that functions to control the transcription of one or more polynucleotides e.g. coding sequences, which is placed 5' upstream of the polynucleotide sequence(s), and which is structurally identified by the presence of a binding site for DNA dependent RNA polymerase, transcription initiation sites and, but not limited to, binding sites for transcription factors, repressors, and any other nucleotide sequences known in the art to act directly or indirectly to regulate the amount of transcription from the ADV-00738PTEPWO promoter. A promoter is said to be operatively linked to a nucleotide sequence or to drive the expression of it when it can initiate transcription of said nucleotide sequence in an expression system using a gene construct comprising said promoter operably linked to a nucleotide sequence of interest using a suitable assay such a RT- qPCR or Northern blotting (detection of the transcript). The activity of said promoter may also be assessed at the protein level using a suitable assay for the encoded protein such as Western blotting or an ELISA. A promoter is said to be capable to initiate transcription if a transcript can be detected or if an increase in a transcript or protein level is found of at least 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 500%, 1000%, 1500% or 2000% as compared to transcription using a construct which only differs in that it is free of said promoter. The term "constitutive" promoter refers to a promoter that is active under most physiological and developmental conditions. An "inducible" promoter is a promoter that is preferably regulated depending on physiological or developmental conditions. A "tissue-specific" promoter is preferably active in specific types of cells / tissues. A “ubiquitous” promoter may be defined as a promoter that is active in many or in any different tissue(s). A” strong promoter” is generally meant to indicate a promoter capable of inducing expression of high levels of a gene product under its control. "Host cells," "cells", "cell lines," "cell cultures", “engineered cells” and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for gene modification include the original progeny of the original cell. The term “primary cell” means a cell isolated from an organism, e.g., a mammal, which is grown in tissue culture (i.e., in vitro) for the first time before subdivision and transfer to a subculture. Primary cells and stem cells can be modified through introduction of one or more polynucleotides, polypeptide, and / or prime editing compositions (e.g., through transfection, transduction, electroporation, and the like) and further passaged. The terms “culture or culturing”, “growth or growing”, referred to cells, are used herein interchangeably and are meant to indicate maintenance of a cell population in vitro or ex vivo, preferably including expansion of the cell population. The term “incubating” or “incubation”, as referred herein to cells and agents according to the invention, means contacting a cell with an agent, e.g., a means for delivering a gene editing agent, and maintaining the contact for a time suitable for delivering the agent into the cell. The term “engraftment” as used herein refers to the ability of cells to populate and survive in a subject following their transplantation, i.e., in the short and / or long term after transplantation. ADV-00738PTEPWO For example, engraftment may refer to the number and / or percentages of hematopoietic cells descended from transplanted hematopoietic stem and / or progenitor cells (e.g., graft-derived cells) that are detected about 1 day to 24 weeks, 1 day to 10 weeks, or 1-30 days or 10-30 days after transplantation. In a xenograft model of human hematopoietic stem and / or progenitor cell engraftment and repopulation, engraftment may be evaluated in the peripheral blood as the percentage of cells deriving from the human xenograft (e.g., positive for the CD45 surface marker), for example. Engraftment may be readily analysed by the skilled person. For example, transplanted hematopoietic stem and / or progenitor cells may be engineered to comprise a marker (e.g., a reporter protein, such as a fluorescent protein), which can be used to quantify the graft-derived cells. Samples for analysis may be extracted from relevant tissues and analysed ex vivo (e.g., using flow cytometry). The terms "treatment", "treating", "treat" and the like, as used herein, refer to the administration of a compound, agent, composition or formulation of the invention to obtain a desired pharmacologic and / or physiologic effect. The effect can be prophylactic in terms of completely or partially preventing a disease or symptom(s) thereof and / or may be therapeutic in terms of a partial or complete stabilization or cure for a disease and / or adverse effect attributable to the disease or control of disease progression. The terms "prevent," "preventing," and "prevention", as used herein, refer to inhibiting the inception or decreasing the occurrence of a disease in a subject. Prevention may be complete (e.g., the total absence of pathological cells in a subject) or partial. Prevention also refers to a reduced susceptibility to a clinical condition. Control of disease progression is understood as the achievement of the beneficial or desired clinical results that include, but are not limited to, reduction of the symptoms, reduction of the duration of the disease, stabilization of pathological states (specifically to avoid additional deterioration), delay of the progression of the disease, improvement in the pathological state, and remission (both partial and total). The control of progression of the disease also involves an extension of survival, compared with the expected survival if treatment is not applied. In particular, in accordance with the present invention, the terms "treatment", "treating", "treat" and the like, as used herein, preferably refer to the administration of a compound, composition or formulation to cure, prevent, delay and / or control the clinical manifestations of a pathology. The term “effective amount” or “therapeutical amount” refers to a quantity of a composition, for example a gene editing agent(s) and / or a gene therapy composition, that can be sufficient to result in a desired activity upon introduction into a subject as disclosed herein. An effective amount of a gene editing compositions and / or gene therapy composition can be provided to the target gene or cell. In some embodiments, the “effective amount” or “therapeutically effective ADV-00738PTEPWO amount” is the amount of a composition that is required to ameliorate the symptoms of a disease relative to an untreated patient. In some embodiments, an effective amount is the amount of a composition sufficient to introduce an alteration in a gene of interest in a cell (e.g., a cell in vitro, ex vivo or in vivo). In some embodiments, an effective amount can be an amount to induce, when administered to a population of cells, a certain percentage of the population of cells to have a correction of a mutation or to bear a transgene. For example, in some embodiments, an effective amount can be the amount to induce, when administered to or introduced to a population of cells, installation of one or more intended nucleotide edits in the target gene. The term “individual” or “subject” herein refers to a mammal, preferably human or non-human mammal, more preferably a human, or a mouse, rat, other rodents, rabbit, dog, cat, pig, cow, horse or primate. Those in need of treatment include those already inflicted as well as those in which prevention is desired (e.g., those with no symptoms but diagnosed with the genetic disorder, etc.). In a first aspect, the present invention is directed to a method for in vitro or ex vivo engineering of a cell, comprising introducing into a cell: a) a gene editing agent comprising, or consisting of: a.i) a nuclease capable of introducing a double strand break (DSB) in a target site in the cell genome; and a.ii) a guide RNA (gRNA) targeting the nuclease to the target site; or comprising, or consisting of: a.i.1) a nickase capable of introducing a single strand break in each DNA strand of the target site, and a.ii.2) a pair of guide RNA (gRNA), each targeting the nickase to opposite strands of the target site; wherein the target site is located within a functional region of a target gene, wherein the target gene is a gene that is haploinsufficient and / or that is present in single copy in the cell; and b) a donor template that comprises: b.i) a knock-in cassette comprising an exogenous polynucleotide encoding a gene product of interest, or a portion thereof; and b.ii) homology arms (HAs) on either side of the knock-in cassette, wherein the 5' homology arm (or “left” homology arm) has a sequence that is homologous (e.g. identical) to a sequence located 5' of the DSB in the target site of the cell genome and ADV-00738PTEPWO the 3' homology arm (“right” homology arm) has a sequence that is homologous to a sequence located 3' of the DSB in the target site of the cell genome; wherein the donor template comprises an exogenous polynucleotide having sequence capable of reconstituting the target gene upon integration of the knock-in cassette into the target site of the cell by homology-directed repair (HDR) of the DSB, such that integration of the knock-in cassette by HDR of the DSB results in a gene edited cell that expresses the gene product of the target gene and the gene product of interest. The invention is also directed to a kit for in vitro or ex vivo engineering of a cell, comprising: a) the gene editing agent, and b) the donor template, as described above; optionally comprising also: c) a cell population. According to preferred embodiments of the present invention, the cell is a mammalian cell, more preferably, the cell is a human cell. Optionally the cell is a male cell (i.e. a cell having one X chromosome and one Y chromosome). Preferably, the cell is a myeloid progenitor cell. In particularly preferred embodiments of the invention, the cell is stem cell, more preferably a hematopoietic stem cells (HSCs) or a hematopoietic stem and progenitor cells (HSPCs). Most preferably, said cell is a CD34+ HSPC. The cell can be a mobilized peripheral blood cell (mPB cell), a cord blood cell (CB cells), or a bone marrow cell (BM cell).In preferred embodiments, the cell is provided after in vitro or ex vivo selection and / or expansion of a population of cells; more preferably the cell is provided after selection and / or expansion of a specific population of cells, such as a population of CD34+ HSPCs. Therefore, preferably, the method of the invention comprises a step of selecting and expanding ex vivo a population of cells isolated from a subject, prior to introducing into said cell the gene editing agent. More preferably, the method of the invention comprises as a step of selecting and expanding ex vivo CD34+ HSPCs obtained and isolated by leukapheresis or bone marrow harvest, prior to incubating said cells with at least one gene editing agent. Optionally the cell that is genetically modified in the method of the invention is an induced pluripotent stem cell (iPSC). In some embodiments the cell is a T cell, a B cell or a NK cell. ADV-00738PTEPWO According to the present invention, suitable target genes are genes that are haploinsufficient in the cell type to be engineered, optionally genes that are present in a single copy in the cell to be engineered. Clearly, suitable target genes include X-linked genes that are present in single copy in male cells, being thus by definition haploinsufficient. In preferred embodiments, the target gene is one of the genes listed in Table 1 that follows. Table 1 Gene Ensemble ID Location Description Evidence / mechanism forhaploinsufficiency in HSPCsRPS19 ENSG00000105372 19q13.2 RibosomalMutated in bone marrow failure Protein S19associated disease (Blackfan Diamond anemia) ATP Binding ABCB7 ENSG00000131269 Xq13.3 Cassette Essential for hemopoiesis (transport subfamily B of heme) member 7 Lethal in mice embryos; ablation of Apoptosis AIFM1 early during hematopoiesis causes hematopoietic stem cell AIFM1 ENSG00000156709 Xq26.1 Inducing Factor Mitochondria (HSC) loss, thymopoiesis blockade, Associated 1 and delayed development of the T- cell, B-cell, and erythroid lineages in mouse model Dyskerin Mutation associated to bone marrow DKC1 ENSG00000130826 Xq28 Pseudouridine failure syndrome (Dyskeratosis Synthase 1 Congenita) FLNA ENSG00000196924 Xq28 Filamin AMutation is pre- or peri-natal phase isdeadly in maleHCCS ENSG00000004961 Xp22.2HolocytochromeCSynthase Mutation lethal in utero in maleMediator MED12 ENSG00000184634 Xq13.1 Complex Involved in initiation of transcription Subunit 12 O-linked N- Lethal in mouse embryonic stem acet cells and essential for HSPCs OGT ENSG00000147162 Xq13.1 ylglucosami ne (GlcNAc) maintenance. OGT disruption in Transferase HSCs leads to rapid loss of HSPCs with increased ROS and apoptosis. GK1 ENSG00000102144 Xq21.1PConversion of 1,3- Phosphoglyceratekinase 1diphosphoglycerate to 3- phosphoglycerate UBL4A ENSG00000102178 Xq28Ubiquitin Like"Housekeeping gene": higher rate of 4Aneonatal death in KO mice Ubiquitin Like Acquired mutations are linked ENSG00000130985 Xp11.23 modif to UBA1 ier Activating clonal hematopoiesis (VEXAS Enzyme 1 syndrome) ADV-00738PTEPWO Preferably, the target gene is selected from: UBA1, RPS19, AIFM1, DKC1, and OGT. More preferably, the target gene is UBA1, RPS19, or OGT. Further genes can be targeted as well in the method of the invention, as long as said genes are haploinsufficient in the target cell. In preferred embodiments of the present invention, the cell is HSPC, and the target gene is selected from: UBA1, RPS19, ABCB7, AIFM1, DKC1, FLNA, HCCS, MED12, OGT, PGK1, and UBL4A, more preferably from UBA1, RPS19, AIFM1, DKC1, and OGT; most preferably, the target gene is UBA1, RPS19, or OGT. In particularly preferred embodiments, the target gene is RPS19, and the cell is a HSPC. A functional region of a target gene is a region that is essential for the functionality of the gene and / or for the expression of the gene product; functional regions include regulatory regions of the target gene and coding regions of the target gene. In preferred embodiments, the target site is located within a coding region of the target gene, such as an exon of the target gene, and the polynucleotide having sequence capable of reconstituting the open reading frame of the target gene upon integration of the knock-in cassette by HDR. The gRNA of the gene editing agent of the method of the invention is preferably selected within the list of gRNAs of Table 2, targeting a target site having sequence (“target sequence”) comprising, or consisting of, any one of SEQ ID NO: 1 to 33. Typically, in the context of gene editing, the “target sequence” is a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a complex comprising the nuclease. The target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, the target sequence is located in the nucleus or cytoplasm of the cell. In some embodiments, the target sequence may be within an organelle of the cell. Table 2 SEQ ID NO: Guide RNA Targeted region on Target sequence ID the target gene 1 AAACGCAGGCCTTACCTGTC RPS19_1 Exon 5 2 GTCAGTTTGCGGCCGCTGTG RPS19_2 Exon 5 3 TACCCCCAGCTTCCACAGCG RPS19_3 Exon 4 4TTGTTGGCAGCTGCCACCTGRPS19_4 Exon 6 ADV-00738PTEPWO 5 TAGACGAGGGCCTTTACTCC UBA1 ex3 #2 Exon 3 6 AGTGAAGCAGACATAGACGA UBA1 ex3 #3 Exon 3 7ACGCGACGTTTCTTGGACAGUBA1 ex2 #4 Exon 48 TCAGCATGTTTCCCGACATC ABCB7_A Exon 5 9 CACCTTGTTTACTCTACTCA ABCB7_B Exon 9 10 AACAAAGCAGATAATGATGC ABCB7_C Exon 7 11 AATGCTATTGTGCAATCCGT AIFM_D Exon 11 12AATAGCTTCATAGCCAACATAIFM_E Exon 1413 CTAGAGGAACATGCCATCGC AIFM_F Exon 2 14 AAGTTGCTAAGTTGGACACG DKC1_G Exon 3 15GGATTTGAACCACATGCAAGDKC1_H Exon 416 AGGGCCTTCTGGACAAGCAT DKC1_I Exon 12 17GCCCGTTACCAATGCGCGAGFLNA_J Exon 418 CTGCCAGGCATCGAGCCCAC FLNA_K Intron 5 and exon 6 19 CGAGGTGACGGGGACTCATA FLNA_L Exon 7 20TCACAATCAGAATAACGAGCHCCS_M Exon 521 GAATAACGAGCAGGCTTGGA HCCS_N Exon 5 22GGATGAGGATATCAGTCAGAHCCS_O Exon 523 AAGGCCGTCAGTTCATCCTG MED12_P Intron 1 and exon 2 24 CTCAGAGATTGCTGCATAGT MED12_Q Exon 4 25CGTCAGCTTCAATCCTGCCAMED12_R Exon 226 TCCCTGTTCTCGTTTGATAT OGT_S Exon 8 27GGATATAGCATACTATGATGOGT_T Exon 1228 GCTCAAAGCCCTGGGTCGCT OGT_U Exon 4 29 CCAGCTCATCAATAATATGC PGK_V Exon 7 30GCTCATAAGGACTACCGACTPGK_W Exon 331 GCACACCATCAGGCCGGCCT PGK_X Exon 3 32 CGACTCTCGGATTATAGCAT UBLA4_Y Exon 3 33 GTTCGATGTCGTCCAGCGTC UBLA4_Z Exon 4 More preferably, the gRNA of the gene editing agent of the method of the invention is a gRNAs targeting a target site having sequence comprising, or consisting of SEQ ID NO: 1, 3, 5, 12, 16, or 27. Said gRNAs show very high cutting efficiency. In this way, the amount of residual non-edited cells (that are not purged out, not bearing any kind of detrimental indels on the target gene) is very low or absent. ADV-00738PTEPWO In further preferred embodiments of the present invention, the target gene is selected from: DCTN2, EIF2S3, GNL3L, LAS1L, NAA10, NUDT21, RNF113A, or TSR2. When targeting said genes, the gRNA of the gene editing agent is preferably selected within the list of gRNAs of Table 3, having sequence comprising, or consisting of, any one of SEQ ID NO: 64-87; more preferably the gRNA of the gene editing agent of the method of the invention is a gRNA having sequence comprising, or consisting of, any one of SEQ ID NO: 64, 67, 70, 73, 76, 79. Table 3 Targeted exon on Genes gRNA sequence SEQ ID NO: the target gene CTGTACTCACAATGCCGGGA 64 1 DCTN2TTCATACTAGACGACAGTGA65 6 ATCGTATTGGAAAAACCAAG66 4 TTGGTCCCTGGAATGTCCGT67 4 EIF2S3TACATGACCAATTGTACCTA68 3 ATGTCCGTAGGAAACTCGTC69 4 TTATTACAAGGAGTTCCGTA70 5 GNL3LATGAGGTGCAGAGGGCACTT71 3 CTTGTAATAAGCCTTCCTCG72 5 GTGACGACCATAAGTTGCAG73 1 LAS1LTTGTTGAGCTCAGTATGTCG74 1 GTGACGACCATAAGTTGCAG75 1 TGCATGTTCATTAGGTCCTC76 2 NAA10GGTGGGAACGCTTCACAGCC77 5 CAATGAGGTGATATGTCCAT78 4 CCTGGTGGTGAACTTAACCC 79 3 NUDT21CAAAAGTATAATTGGTAAGA80 2 TTCTGATTGTACATGAGCAC81 2 TGTAATCTGAACGGTCATGG82 1 RNF113AATGGCAGAGCAGCTTTCTCC83 1 AAGCCCAAGGATACGTCTAT84 1 GAGGATTACTTCATGCGCAA85 2 TSR2CCTCTGGAAGTGGTGGAACA86 4 ATGTTCCACCACTTCCAGAG87 4 ADV-00738PTEPWO In further preferred embodiments of the present invention, the target gene is selected from anyone of the genes listed in Table 4. For said genes, the gRNA of the gene editing agent of the method of the invention is preferably selected within the list of gRNAs of Table 4, having sequence comprising, or consisting of, any one of SEQ ID NO: 88-325. Table 4 Genes gRNA SEQ ID NO:Targeted Exon onthe target geneACCACCATACCAATAGCTGT88 3 ACTL6A GGTGCCTCTGACATGAGAAC89 4 AAACAGCCAGTTCCAGAGCC90 4 ARHGEF1 CGATGATGCTGACGGGAACC91 3 GCTTTCCTCACAGATTTCGA92 3 ARPC2 GATTCCATTGTGCATCAAGC93 5 CCTTCGAATGAGGTAGCGAG94 3 ARRDC3 GTATCCCCACTAGAATACAC95 1 TCACCCTTGCTGTTGTTGGA96 1 ATF4 AGATGACCTTCTGACCACGT97 2 TTCTCTTCTAGGTTTTGGCT98 4 ATP2A2 GAAGTTAACCTTATATCAGC99 6 TTTTCTTTTCAGGTGTTTTG100 2 ATP6AP2 AGGTTACCCACTGCGAGTCC101 3 AAAAATGTCTCAGAGCAACC102 2 BCL2L1 AGCATATCAGAGCTTTGAAC103 2 TACAAAGGCAGTAAGGCTCC104 2 BCL3 GTAACCTGCCAGCTGTGCAC105 3 TTGGGTGCATCTGCTGCTCC106 6 CCT3 CATGACTCCACGCAAGACAC107 8 TTGCTCCGCTTCTTCTAACA108 4 CCT5 GGCCACCATCTTAAGCATGA109 3 GGATGAAATTCTGAAAGCAG110 2 CDC5L AGGACCATTGCTCCAATCAT111 3 TACTTTGTTTCAGGTACCTA112 3 CDK1 GGGTTCCTAGTACTGCAATT113 3 ACCCGCGTTCATGCAACGCC114 1 CEBPB GGCCAACTTCTACTACGAGG115 1 GGCCTCCCGCTGGAACTCGA116 2 CHMP4B CTGACGGCCGCCAAGAAGCA117 1 ATGTCAGTCTCGTGATCTCG118 3 COPS4 GCCTAGAGTCATTTCATTTG119 3 COPS5GTACTGCAAAATCTCAGCAT120 2 ADV-00738PTEPWO CCAACAAGAACAATATCCGC121 4 TGCAGACACGATGAGGCGAG122 2 CORO1C CATATCGTCCAAGTTTATAA123 5 TGTGTCTAGGAAGAAGAAGC124 2 CPEB1 GGCACAAGTCATTTGCATCT125 3 AAAGGTGAAAAACAAAGCCC126 2 CRNKL1 CTGGATAAAATACGCACAAT127 3 CTGGGACATACTCAGCTGCC128 2 CSTF3 CTCCAAGCATCAAGGTCATA129 2 CTACTCTTAAAGGAAACTGG130 7 DCAF8 CCACTCTCAAAGTCCAGTAC131 4 TCTTTCAGGACACTTTACTT132 2 DDB1 TCGTGTTTTTGGCAATCAAC133 2 ACCTGAGCCCCCAGCATGGC134 1 DEDD CCTTGGTTCTGGATCACTGA135 2 GGTACTATGGCTTCCTCGTC136 2 DR1 TCGTTGGCCACCCGGACATT137 2 CTCCCCGCTAGAGTATGCTC138 3 EIF1AX AGGAGGTAAAAACAGACGCA139 2 TTGTTTAAATTGCAGAATGC140 2 EIF2S1 GTACTTGTCATCAAAGACCC141 4 CCTGGCAGGCGCGCCCCTGG142 2 FAU CCAGGAGCTACACACCTTCG143 1 AAATATTTGCTGTGTCTCAG144 2 FGF5 GCCACTGATAGGAACCCTAG145 1 AAGATTGAAACAGGATTCCA146 4 GEMIN8 TGGATCCTACTGCTGTAACG147 4 TGCTGCTGCCTTGGACACCT148 2 GNG3 GGGCATCACAGTAAGTCATC149 2 CCACATCAGTGTGAAGCCCC150 2 GPKOW CGATGGCCATTCTGGATCAA151 2 TGTTCTTTGCAGACGATGTC152 2 HMGB3 AGGATCCTAATGCTCCCAAA153 2 CTGGAAGTAAATATACAGGA154 3 HMGCR TGTCCCCACTATGACTTCCC155 2 TCCCTTTTGACAGGGCCTGG156 2 HSD17B10 TGGACCTGCCCAACTCGGGT157 2 TTACGATATGAAATAGATAC158 5 HSPA14 GGTGTGGTTGCAAATGATGC159 2 AGCGTCGGCGTGTTCAAGAA160 2 HSPA5 CGTCAAAGACCGTGTTCTCG161 2 HTATSF1AGATTTCATTGCTACATATC162 2 ADV-00738PTEPWO ATGAGCGGCACCAACTTGGA163 1 GACCATTTAATTTGGCAGAG164 2 KIF11 GAAGTTAGTGTACGAACTGG165 2 AGGACGGGGACAAGTTCTGG166 4 LSM4 GGAGACGTACAATGGACACC167 3 TACCATCGGACTATTTTGAC168 2 MCTS1 CAATTGATAGAGCAATTTCC169 2 TCGCCCAGGTGAGATTTCAA170 2 MFAP1 ATAGTGGAACCTGAAGTGGT171 3 ACCGTAACAGGTAACTGCAA172 3 MMGT1 AATATGAACTATACCGTAAC173 3 CGGGGAACCAGAGCTGGGCC174 3 MRPS12 CACAAGTTAGGGACGTGTTG175 2 TTTCTCTAAGGTCATCGAGC176 5 MYBL2 TCTGGATGAGCTGCACTACC177 2 TTTATTTTTAAGGCCATGGT178 3 NAA30 GACGAAGAGCACGAAGGCGG179 2 GAGGAGGAGCCATTTTCTTG180 2 NCL ATGGAGACTACACCAGCCAA181 4 AAAAGCATTCACAGCTCTGA182 4 NOP58 GGTGCTGTTTGAAACGTCTG183 1 GGACTTGTGCTGCTAAGTTG184 2 OGDH TGGGACTAGTTCGAACTATG185 2 ATGGCGGCGACGGAGCTGAG186 1 OSBP CGCGACCACCGTCCCTGACG187 1 GGCTTTGTACTGGACGAACC188 3 PAF1 GGCTATTGCAGTACTTGACT189 2 GACCAGGCGCGCCTCGAACA190 1 PCNA GGACTCGTCCCACGTCTCTT191 1 ACAATGCAGTCGAGACACTG192 3 POLR2H AATACAACCCCACTGATGAT193 4 CAGGGTGATTTTGTAGACAG194 4 PPP6C GCTAGACCTGGACAAGTATG195 1 GATGGAAGACAGGCATGCAG196 2 PRMT5 GAACCTGCTAAGAATCGGCC197 2 TACAGTCTCTAACGAAGTGC198 2 PRPF19 GATGTCGATGAGCTGCTCCT199 2 AGGCTGTTGCCCAGCTCCTG200 6 PRPF31 ACTATCCCATAGCTTGGCGA201 2 CAATATGCAAAATTCTCACA202 2 PRPF39 TTCACATTGGGAGAGTCATC203 2 PRPF4GTCGTCGGGTGCTTTAGTTT204 2 ADV-00738PTEPWO GGGAAAGACGGACTTAAAGC205 2 TTCTAGATATTTGCCGAGAG206 6 PSMC6 TGTGTTCAAGCAACTTCTTG207 1 ACCCTTACAGGCTTCCGATA208 3 PSMD12 ACGGGATGTCGATACCATAT209 3 GTTTCCGTTTCAGCCACCTT210 3 RAN TTGTTGCCACACAACACAAT211 4 TCATGTCACCTGGTTACATC212 2 RBBP4 ATCATTAGGGAGCTGCACAC213 3 TTCAATTTTTAGGAAGCTGA214 3 RBBP5 ATCTGGGATTTCTTGACAAG215 3 TTCCAAAATGGCGGCAGCGA216 1 RBX1 ACCCCGAGCGGCACCAACAG217 1 ACAGGTGGATTCGAAAGCTA218 2 RPA2 AAGCAGCTGAGATATAGTAC219 3 TTACCTCTGCAACGGACTGA220 3 RPL15 AAAACCATTTACCTCTGCAA221 3 TCTGTGTGTCTAGTATGCTC222 2 RPL19 TCCGGAAGCTCATCAAAGAT223 3 AAACCAGAGCTCAGAAAAAA224 3 RPL23 AATCCGGAATTTCGCACCAG225 2 CTTTAGGAGGGGCAGGAGCT226 2 RPL23A AGTACTGACTTGTTTCTCCT227 2 TCAGGCTCCCAAACGTACCC228 4 RPL29 GTAGGGGCCTGGGTACGTTT229 4 CGTGCGGGAAGTCGACAGGC230 2 RPL3 CATGGGTGGTGTCTCTACAA231 3 CTTCAAGAAGCGTGCACCTC232 3 RPL31 GCTTCAAGAAGCGTGCACCT233 3 AAAAAATATTTTTAGATGGC234 2 RPL6 TCTGGAATACATGGCAGATC235 2 TCTAGTCGACATTACTCTGA236 3 RPL9 CTAGTCGACATTACTCTGAA237 3 TTGTTTTTTGTAGCAACTAT238 2 RPLP0 ATTGTGGGAGCAGACAATGT239 2 TTACAGTCTCTCAAGTCCCG240 3 RPS10 GGAACCATACCTTTAGGCCG241 3 CCGATGTTCTTGTAGTACCG242 2 RPS11 CTGGTAATGTGTCCATTCGA243 3 TCGCGTTTAAGCATTGCTGC244 3 RPS12 CACGTACTTGTCTAAGGCTT245 3 RPS13GTAATCCTGAGAGATTCACA246 4 ADV-00738PTEPWO CAACACCATGTGAATCTCTC247 4 TTATCTTTTGTAGGTTACAT248 3 RPS15A TACTCTTGAGAGCATCTGCC249 2 TGGTGATCACACGTTCCACC250 4 RPS18 AGACATTGACCTCACCAAGA251 3 TACCCCCAGCTTCCACAGCG252 4 RPS19 AAACGCAGGCCTTACCTGTC253 5 TAATTTTTAGGCAAGTGTCG254 2 RPS23 GCAACCGTCATTGGGTACAA255 3 TTGGATTAGTTTGTCGCTGA256 2 RPS3 AGGTGCGAGTTACACCAACC257 2 CTTAGAAAATGGATCAACCC258 2 RPS3A CTTACTGGTTCCTTGGGTCC259 2 TGGGGACCGGTGGATGGACG260 2 RPS4X TCTCAACTTGTGGGGACCGG261 2 TTTCTTTAGGAAATTGAAGT262 4 RPS7 GCATGTCGTCTTTATCGCTC263 4 TCCACATGCAGGCATCTCTC264 2 RPS8 AATTCCCCACGTCCAACCTC265 3 CCACAACTATTAGACCCTCC266 2 RTL3 CAAGACTGTTGGGATCTCAT267 2 TTTGTAGACAGCTCTGGCTC268 3 RUVBL1 TAAGGTCCCCTTCTGCCCAA269 3 CACCATGATGTTCCGAGACC270 5 SAMD4B ATCCTCGCTGGCTGGTTCAA271 5 AGCAACAGTGGGCATGTCTG272 2 SAP18 CGGGTCTTCACCACCAATAA273 2 TGGTATAGGAGCTAGAGATC274 2 SCD TGACCCCACCTACAAGGATA275 2 GTTTTAGGAATAAGACGAGT276 2 SERBP1 TCGAATCTTCGTTCACGAGG277 2 CTGAAATTGCAGATTACGAA278 4 SF3A3 GGAACGGCTCATGGACGTCA279 1 ATGCTGGGCAAAACGAGGAG280 5 SFPQ GGCTTCTTCCAACAGTTCAT281 3 TTTTCCTAAACTACTACTCA282 2 SHOC2 ATTGTGCTGCAAGTCAAGGT283 3 GGGGAGCAGAACCACTCTCC284 2 SLC25A53 CGGAACACAACCTTATAGAT285 2 GCTCCTTGCGTGCAGTTCGA286 4 SLC38A5 GAGCAAGCCGGTCCAGTTCA287 3 SMC6TAATAGACTGCAGCAGAAGT288 3 ADV-00738PTEPWO ATGCTTGGACCTTTTAAGTT289 3 TTGAGTTGACAGAAGGTCTT290 3 SMNDC1 CAAGTTGAAGCTGCATTATC291 2 CCAAAATCACAGAATGAAGG292 1 SNIP1 AGGGAGCCGGCGAAGACACC293 1 GCCATCTGCGTGTTTGTAAG294 8 SNRNP70 GGTATGGAATAGGGTCACGG295 2 CATTTCTCCTTGCAGACGGT296 2 SNRPB GTGCTTGTCAAAAGCCTTGA297 2 ATTATTTTCCTCTTTAGGTG298 3 SNRPD1 TGTTCCGTTCTTCAATTCAA299 2 CACTCTTGGGCTTGTTGAGG300 2 SNRPD2 CGTGAAGGAGATGTGGACTG301 3 AGTCCATTGAGGAAAGGTTT302 2 SNRPF GTGATGGTGAAACTTAAGTG303 2 CTAGCTGGTTCTGGAGATGA304 2 SNX2 CGTGATCTTTGATAGATCCA305 3 CCCAGCTTGGGTCGGTAACA306 1 SRF AGGTTGGTGACTGTGAACGC307 3 ACATGCATGTCTTCCAGATG308 3 SUPT6H ACAAATTTCTTGGTGACTCG309 2 CAGCCGCAAGATGGCGGCGC310 1 TAF5 GTTGGGACAACTCTGCCCGA311 2 AAACTCTACAGTGAAAATGA312 2 TCEAL4 GAAGGAATGGCTTCAAACCA313 2 AGAGGGAATACTCAGGGCTG314 5 TRNAU1AP GATGAAGTTCTCATCCATGT315 2 CGCCGCTCGAGAGATGATGC316 1 TWIST1 GGCCGGCGAGACTGGCGAGC317 1 CAGGTATGTGTTGGGCCATG318 5 UBA1 TCGGACAACACGGACTGGGC319 3 CTTTTTTCTTCTTCAAGGTG320 5 UPRT CCAAGGTGATTCTCCTCACG321 1 TCACGCATCTATGTGGCCCT322 4 UXT GCACTCGGAGTTATATATGC323 3 CTCGGTCACTGCCTTCATGC324 1 YWHAQ AGATAGAAGACCTTACTCTC325 2 The gRNA of the gene editing agent targets the nuclease to the target site in the genome of the cell (van der Oost et al. (2014) Nat. Rev. Microbiol.12: 479-92). ADV-00738PTEPWO Preferred nucleases suitable for gene editing of a target gene according to the present invention include zinc finger nucleases (ZFNs), transcription activator like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR) / Cas nuclease (Gaj, T. et al. (2013) Trends Biotechnol.31: 397-405). Meganucleases (Silve, G. et al. (2011) Cur. Gene Ther.11: 11-27). According to particularly preferred aspects of the invention, the gene editing agent introduced in the cell in the method of the invention comprises a nuclease being selected from: zinc-finger nuclease, a transcription activator like effector nuclease (TALENs), and a Cas nuclease. In other particularly preferred embodiments, the gene editing agent introduced in the cell in the method of the invention is a gene editing agent comprising a nickase for double nick editing. According to particularly preferred embodiments of the invention, the gene editing agent comprises a gRNA, which sequence-specifically binds to the target site, and a Cas nuclease (e.gCas9 or Cas12a), or comprises two gRNAs which sequence-specifically binds to opposite strands of the target site and a nickase (e.g. nCas, preferably Cas9D10A 28), said gene editing agent introducing a double strand break (DSB) in the target site. The nuclease (or nickase) can be introduced in the cell as DNA encoding the same, or as RNA transcript thereof. In some embodiments, the gene editing agent is introduced in the cell by a viral vector comprising a polynucleotide encoding the gene editing agent. Therefore, the method of the invention preferably comprises a step of transducing the cell with a viral vector comprising a polynucleotide encoding the gene editing agent. Viral vectors suitable for delivering the at least one gene editing agent include, but are not limited to, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes viral vectors, retroviral vectors, lentiviral vectors and baculoviral vectors. More preferred viral vectors are lentiviral vectors (LVs), or integration-defective lentiviral vectors (IDLVs). In some embodiments, the gene editing agent is delivered in the cell by a non-viral vector. Non-viral delivery systems include, but are not limited to, DNA transfection methods. Typical transfection methods include electroporation, DNA biolistics, lipid-mediated transfection, compacted DNA-mediated transfection, liposomes, immunoliposomes, lipofectin, cationic agent-mediated transfection, cationic facial amphiphiles (CFAs) (Nature Biotechnology (1996) 14: 556), nanoparticles, and combinations thereof. Any RNA of the gene editing agent, such as the gRNA or a nuclease-encoding mRNA, can be delivered in the form of RNA. The RNA can directly contact the target gene or can be ADV-00738PTEPWO introduced into a cell using any suitable technique for introducing nucleic acids into cells (e.g., microinjection, electroporation, transfection). An exogenous polynucleotide template is introduced in the cell for recombination into the targeted locus comprising the target site. This is referred to as “donor template”. Preferably, the donor template is a DNA donor template, more preferably a double stranded DNA donor template. Preferably, the sequence of the exogenous polynucleotide of the donor template capable of reconstituting the target gene is a codon-usage optimized sequence, that it is not recognized and / or disrupted by the gene editing agent. In some embodiments, the donor template does not comprise a reporter gene, e.g., a fluorescent reporter gene or an antibiotic resistance gene. The donor template according to the invention comprises a knock-in cassette in between two homology arms for HDR integration of the knock-in cassette in the target gene. In particular, the 5' homology arm (or “left” homology arm) of the donor template has a sequence that is homologous, preferably identical, to a sequence located 5' of the DSB in the target site, preferably contiguous to the DSB, and the 3' homology arm (“right” homology arm) of the donor template has a sequence that is homologous, preferably identical, to a sequence located 3' of the DSB, preferably contiguous to the DSB, in the target site of the cell genome. Preferably, the 5’ and 3’ homology arms of the donor template have sequences having at least 95% of homology with the sequences respectively located 5’ or 3’ of the DSB; preferably, the 5’ and 3’ homology arms are homologous to sequences respectively located at 5’ or 3’ of the DSB, while diverging from the target sequence in the PAM and / or gRNA target site (e.g. by excluding or degenerating the 10-20 bp around from the DSB); preferably the 5’ and 3’ homology arms are homologous to sequences at 5’ or 3’ of the DSB and have a length of from 100 bp to 2.5 kb, preferably of from 200 bp to 1.5 kp, more preferably of from 200 bp to 800 bp. When the target site is located within an exon of the target gene, in accordance with preferred embodiments of the invention, the exogenous polynucleotide having sequence capable of reconstituting the target gene has sequence comprising, or consisting of, a sequence homologous to the endogenous sequence of said exon, or to a portion thereof. More preferably, said sequence is a codon-usage optimized sequence, that it is not recognized and / or disrupted by the gene editing agent. In some embodiments, the exogenous polynucleotide having sequence capable of reconstituting the target gene, or a portion thereof, is part of one of the homology arms. ADV-00738PTEPWO In some embodiments, the exogenous polynucleotide having sequence capable of reconstituting the target gene, or a portion thereof, is part of the knock-in cassette. In some embodiments, the target site is within an exon of the target gene and the exogenous polynucleotide having sequence capable of reconstituting the target gene has a first portion whose sequence is a codon-usage optimized sequence corresponding to the endogenous sequence of the portion of exon that is upstream the DSB and a second portion whose sequence is a codon-usage optimized sequence corresponding to the endogenous sequence of the portion of exon that is downstream the DSB, wherein the first portion is part of the left homology arm and the second portion is part of the knock-in cassette. Such an embodiment is exemplified in Fig.1 C and D. In some embodiments, the target site is within an exon of UBA1 gene and the HAs of the donor template have sequences homologous to sequences of the target gene that are located 5’and 3’of the DSB in said exon. According to preferred embodiments, the target site is within exon 3 of UBA1 gene and the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 40 and 41, respectively. In some embodiments, the target site is within an exon of RPS19 gene and the HAs of the donor template have sequences homologous to sequences of the target gene that are located 5’and 3’of the DSB in said exon. According to preferred embodiments, the target site is within exon 5 of RPS19 gene and the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 44 and 45, respectively. In some embodiments, the target site is within an exon of OGT gene and the HAs of the donor template have sequences homologous to sequences of the target gene that are located 5’and 3’of the DSB in said exon. According to preferred embodiments, the target site is within exon 12 of OGT gene and the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 50 and 51, respectively. Preferably, the knock-in cassette comprises an exogenous polynucleotide encoding a gene product of interest that is the product of an endogenous gene that is missing and / or altered in the target cells and that it is meant to be added and / or corrected through HDR gene editing of the cells. More preferably, the gene product of interest is different from the gene product of the target gene. For example, when the target gene is UBA1 gene, the gene product of interest is not UBA1. Advantageously, the method and kit of the invention can be used as a platform for expressing any gene of interest integrated in a locus that is safe and that takes advantage of the selection ADV-00738PTEPWO approach of the invention, wherein the cells that do not integrate the knock-in cassette or that present undesired outcomes of the gene editing are spontaneously purged out, while cells that correctly integrate the knock-in cassette by HDR are indirectly enriched. The method and kit of the invention provide indeed a one-size-fits-all platform that can be adapted for the treatment of various diseases by selecting the exogenous polynucleotide of the donor template while keeping other components unchanged). Advantageously, the invention is significantly more efficient and cleaner in terms of genotoxic outcomes compared to a standard HDR-mediated correction either in the disease specific locus (i.e. gene correction) and to a standard safe harbour approach one (such as target integration into AAVS1 locus) because of the spontaneous purge out of NHEJ byproducts. Furthermore, the exogenous polynucleotide of the donor template can be put under the control of even very strong promoters, resulting in strong gene expression while mitigating genotoxic concerns arising from transactivation of neighbouring genes from the strong promoter itself, or even under the control of a constitutive endogenous promoter, thus fully abrogating genotoxic concerns stemming from promoter activity. An exemplary disease that can be treated by means of the method and kit of the invention is X- ALD. X-ALD is a very severe disease which affects the central or peripheral nervous system and the adrenal cortex. The cerebral ALD form is particularly severe, with childhood onset, rapid disease progression with to neurological decline and premature death. There is no enzymatic replacement therapy available, and hematopoietic stem cell transplantation is an unsatisfactory therapeutic option. X-ALD is due to mutations of the ATP binding cassette subfamily D number 1 (ABCD1) gene, which encodes for adrenoleukodystrophy protein (ALDP), which is required for transport of very long chain fatty acid (VLCFA) into the peroxisome. This defective transport leads to the impaired degradation of VLCFAs and subsequent accumulation of VLCFAs in mainly the white matter and axions of the central nervous system and the adrenal system. Accumulation of VLCFA is considered to be the culprit of demyelination, cerebral inflammation and blood-barrier disruption. Mitochondrial dysfunction evoked by oxidative stress, endoplasmic reticulum stress and lipid-induced cell death are also caused by the accumulation of VLCFA. This combination of factor leads to neurodegeneration and / or adrenocortical insufficiency. A clinical trial with lentiviral vector gene therapy18has proven to be very effective for the treatment of patients; in this case a third generation lentiviral vector was used expressing wild- type ABCD1 cDNA under the control of the MND (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer binding site substituted) promoter, a very ADV-00738PTEPWO strong promoter which can enhance transgene expression especially in myeloid-derived cells (including microglial cells). Subsequently to the trial, the gene therapy product (Elivaldogene autotemcel, eli-cel) was approved for patients. Nevertheless, recent data27have proven this effective therapy to be associated with high risk of insertional mutagenesis; hematologic cancer developed in a subgroup of patients who were treated with eli-cel; the cases are associated with clonal vector insertions within oncogenes and clonal evolution with acquisition of somatic genetic defects. Advantageously, the method and kit of the invention can be used to insert a codon-optimized sequence of coding sequence of ABCD1 gene under the control of a strong promoter within of target genes according to the present invention (for instance, but not limitedly to, UBA1, OGT and RPS19) providing an effective therapy of X-ALD, which is safer as compared to currently available gene therapy, by avoiding semirandom, genome-wide unregulated MND promoter activity. Therefore, preferably, the donor template of the method and kit of the invention comprises, as exogenous polynucleotide encoding the gene product of interest, an exogenous polynucleotide encoding ABCD1 gene product, more said exogenous polynucleotide having sequence SEQ ID NO: 59 (that is the codon-optimized coding sequence of ABCD1). Preferably, the knock-in cassette comprises an exogenous promoter, operably linked to the exogenous polynucleotide encoding the gene product of interest and driving expression of the gene product of interest. In preferred embodiments, said promoter is a strong promoter, that induces the expression of high levels of the gene product of interest. Strong promoters that can be used to drive expression of the gene of interest (GOI), in accordance with preferred, non-limiting, embodiments of the invention are: Spleen Focus- Forming Virus promoter (SFFV), MND promoter, gp91phox promoters, EIF1a promoter, or PGK promoter16. Preferably, said promoter is a Spleen Focus-Forming Virus promoter, SFFV, having sequence comprising or consisting of SEQ ID NO: 37 (or SEQ ID NO: 54 when the gene of interest in the knock-in cassette is in an antisense direction as compared to the transcription of the native gene). In some embodiments, said promoter is a MND promoter (SEQ ID NO: 55, or its reverse complement when the GOI in the knock-in cassette is in an antisense direction as compared to the transcription of the native gene) or a chimeric gp91phox -SP146 synthetic promoter (SEQ ADV-00738PTEPWO ID NO: 56 or its reverse complement when the GOI in the knock-in cassette is in an antisense direction as compared to the transcription of the native gene). Advantageously, the method of the invention admits the use of strong and very strong promoters to induce expression of the gene product of interest, in view of the safety profile of the target loci of HDR integration. In some embodiments the knock-in cassette does not comprise an exogenous promoter as the expression of both the target gene and the gene of interest is driven by the endogenous promoter of the target gene upon integration of the knock-in cassette. In some embodiments, the knock-in cassette comprises one or more regulatory elements that enable expression of the gene product of interest and / or of the target gene product as separate gene products. When the expression of the gene of interest is under the control of the same promoter driving expression of the target gene product, the knock-in cassette comprises an IRES or 2A element to separate the expression of the target gene and of the gene of interest. Preferably, the polynucleotide of the knock-in cassette encoding the gene product of interest is under the control of an exogenous promoter and the knock-in cassette comprises a polyadenylation (polyA) sequence downstream of sequence encoding for the gene product of interest, and optionally a 3' UTR sequence upstream of the polyA. In some embodiments, the target site is within an exon of the target gene, that is followed by one or more further exons in the endogenous gene. In these and other embodiments, preferably the exogenous polynucleotide having sequence capable of reconstituting the target gene comprises a splicing site and the polynucleotide encoding the gene product of interest is under the control of an exogenous promoter and comprises a polyadenylation signal. In this way, the gene product of interest is transcribed separately from the endogenous gene product of the target gene upon integration of the knock-in cassette. Moreover, the endogenous target gene will be reconstituted with its exons in frame upon integration of the knock-in cassette. Preferably, the target site is within exon 3 of UBA1, and the knock-in cassette comprises, from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting UBA1 gene being SEQ ID NO: 36, consisting of a codon-usage optimized sequence corresponding to the endogenous sequence of the portion of exon 3 of UBA1 that is downstream the DSB in the endogenous gene, with a splicing donor domain (SD); an exogenous polynucleotide (gene of interest, GOI) encoding for a gene product of interest, under the control of an exogenous promoter, more preferably of a strong viral promoter, most ADV-00738PTEPWO preferably SFFV promoter (SEQ ID NO: 37); and a polyadenylation (polyA) signal, more preferably a bGH polyadenylation (polyA) signal (SEQ ID NO: 39), (see Fig.4 A “sense”). Optionally, the knock-in cassette for integration in exon 3 of UBA1 by HDR can bear the gene of interest in an antisense direction as compared to the transcription of the native gene, said cassette comprising in sequence from the 5’ end to the 3’ end: a polyA, preferably having sequences SEQ ID NO: 52, the GOI, and the promoter, preferably having sequences SEQ ID NO: 54 (see Fig.4 A “antisense”). In the donor template, said knock-in cassettes are between homology arms (HAs) for HDR insertion in the target site of exon 3 of UBA1 gene and reconstitution of the UBA1 gene. Preferably, the target site has sequence comprising, or consisting of, SEQ ID NO: 5 and the left and right HA have sequences comprising, or consisting of, SEQ ID NO: 40 and 41, respectively. In some embodiments, the target site is within last or second-last exon of the target gene. In these and other embodiments, preferably the exogenous polynucleotide having sequence capable of reconstituting the target gene comprises and the polynucleotide encoding the gene product of interest can be under the control of the endogenous promoter upon integration of the knock-in cassette, preferably being separated in the knock in cassette by a IRES or 2A element, more preferably the knock-in cassette including a polyA signal. Preferably, the target site is within exon 5 of RPS19 and the knock-in cassette comprises in sequence, from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting the target gene being SEQ ID NO: 42, consisting of a codon-usage optimized sequence corresponding to the endogenous sequence of the portion of exon 5 of RPS19 gene that is downstream of the DBS in the endogenous gene and of exon 6 of RPS19 gene, a P2A domain having sequence SEQ ID NO: 43, an exogenous polynucleotide (gene of interest, GOI) encoding for a gene product of interest, and a polyadenylation (polyA) signal, more preferably a bGH polyA having sequence SEQ ID NO: 39 (see Fig.4 B). In some embodiments, the target site is within exon 5 of RPS19 and the knock-in cassette comprises in sequence, from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting the target gene being SEQ ID NO: 42, consisting of a codon-usage optimized sequence corresponding to the endogenous sequence of the portion of exon 5 of RPS19 gene that is downstream of the DBS in the endogenous gene and of exon 6 of RPS19 gene, a P2A domain having sequence SEQ ID NO: 43, an exogenous polynucleotide (gene of interest, GOI) encoding for a gene product of interest; the cassette does not comprise a polyadenylation signal and, upon integration in the ADV-00738PTEPWO target site, a splicing donor (SD) domain (SEQ ID NO: 60) is present at 3’ of the knock-in site, provided by the right homology arm (SEQ ID NO: 45) whose sequence comprising a splicing donor domain sequence at its 5’, thus conserving the expression of the endogenous 3’UTR of the RPS19 gene (Fig.7A). In the donor template, said knock-in cassette is between homology arms (HAs) for HDR insertion in the target site of exon 5 of RPS19 gene and reconstitution of the RPS19 gene. Preferably, the target site has sequence comprising, or consisting of, SEQ ID NO: 1 and the left and right HA have sequences comprising, or consisting of, SEQ ID NO: 44 and 45, respectively. In further embodiments, the target site is within exon 4 of RPS19; preferably, the knock-in cassette comprises in sequence, from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting the target gene being SEQ ID NO: 61 consisting of a codon-usage optimized sequence encoding the portion of exon 4 of RPS19 gene that is downstream the DSB in the endogenous gene with a splicing acceptor (SA), an exogenous polynucleotide encoding for a gene product of interest, under the control of a strong viral promoter, more preferably SFFV promoter (SEQ ID NO: 37), and a polyadenylation (polyA) signal, more preferably a bGH poly A (SEQ ID NO: 39), in antisense orientation. In the donor template, said knock-in cassette is between homology arms (HAs) for HDR insertion in the target site of exon 4 of RPS19 gene and reconstitution of the RPS19 gene. Preferably, the target site has sequence comprising, or consisting of, SEQ ID NO: 3 and the left and right HA have sequences comprising, or consisting of, SEQ ID NO: 62 and 63, respectively. In further embodiments, the target site is within exon 12 of OGT gene and the knock-in cassette comprises in sequence from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting the target gene being SEQ ID NO: 49, consisting of a codon-usage optimized sequence encoding the portion of exon 12 of OGT gene that is downstream of the DSB in the endogenous gene with a splicing donor domain (SD), and an exogenous polynucleotide encoding for a gene product of interest, under the control of a strong viral promoter, more preferably SFFV promoter (SEQ ID NO: 37), and a polyadenylation (polyA) signal, more preferably a bGH polyA (SEQ ID NO: 39). In other embodiments, the target site is within exon 12 of OGT gene and the knock-in cassette comprises in sequence from the 5’ end to the 3’ end: an exogenous polynucleotide having sequence capable of reconstituting the target gene being SEQ ID NO: 49, consisting of a codon-usage optimized sequence encoding the portion of exon 12 of OGT gene that is downstream of the DSB in the endogenous gene with a splicing donor ADV-00738PTEPWO domain (SD), and the cassette for expressing a gene of interest in antisense direction as compared to OGT gene (Fig.7B). In the donor template, the knock-in cassette is between homology arms (HAs) for HDR insertion in the target site of exon 12 of OGT gene and reconstitution of the OGT gene. Preferably, the target site has sequence comprising, or consisting of, SEQ ID NO: 27 and the left and right HA have sequences comprising, or consisting of, SEQ ID NO: 50 and 51, respectively. The donor template can be delivered to the cell by means of a viral vector. Preferably the viral vector is an adeno-associated vector (AAV), or an integration-defective lentiviral vector (IDLV). Said viral vector can be optimized for maximal transduction efficiency and stable constitutive transgene expression in target cells. Optionally, the donor template can be delivered to the cell by means of a non-viral vector Non-viral vectors are a heterogeneous group of delivery vectors that comprise polyplexes, lipid nanoparticles, non-lipid nanoparticles, virus-like particles or combinations of these. In comparison with viral vectors, this group is characterized by low cytotoxic, immunogenic and mutagenic profiles. Moreover, they also present high cargo capacity. Most lipids consist of positively charged headgroups which bind with the anionic phosphate groups of nucleic acids via electrostatic interactions to form lipid nanoparticles. Polyplexes are formed when polyanionic nucleic acids compact with polycationic polymers. Non-lipid nanoparticles may comprise carbon- or metal- based nanoparticles, examples of which include carbon nanotubes, graphene or carbon quantum dots (CQDs) and gold or iron oxide nanoparticles. Virus-like particles are virus-derived structures made of one or more different molecules with the ability to self-assemble, mimicking the form and size of a viral particle, therefore they maintain the ability to transduce the target cell, but they lack the viral genetic material. Non-viral delivery systems include DNA transfection such as electroporation, lipid mediated transfection, compacted DNA-mediated transfection; liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof. Preferably, the donor template is delivered to cells in a transfected plasmid or as linear or circular naked DNA. The delivery of the donor template by a vector system according to the present invention may be used alone or in combination with other treatments or components of the treatment. ADV-00738PTEPWO Preferably, when any of the gene editing agent and / or donor template is introduced into a cell, delivered with a viral vector, according to the method of the invention, the step of transducing the cell with the viral vector includes stimulation of cells in the presence of a human cytokine mix, more preferably for about 22-hour, followed by the addition of the viral particles, preferably for about 14 hours upon transduction. Preferably, when the cell is transduced a cell with a IDLV viral vector, at least one viral transduction enhancer, more preferably PGE, CsH, CsA or a poloxamer, and / or at least one expansion enhancer, more preferably UM171, UM729, StemRegenin1 (SR1), diethylaminobenzaldehyde (DEAB), LG1506, BIO (GSK3β inhibitor), NR-101, trichostatin A (TSA), garcinol (GAR), valproic acid (VPA), copper chelator, tetraethylenepentamine, and nicotinamide, is added to the cell culture before transduction, according to optimized protocols, for instance as described in WO2013049615, WO2018193118, WO2013127964 and in Delville et al. According to preferred embodiments of the method of the invention, the cells are further genetically engineered to express an engraftment enhancer. More preferably said engraftment enhancer is CD47 and / or C-X-C chemokine receptor type 4 (CXCR4). According to preferred embodiments, the cells are cultured in the presence of an inhibitor of senescence, such as inhibitor of MAPK / ERK signaling, an IL-1 inhibitor and / or an NF-κB inhibitor. Preferably, the inhibitor of MAPK / ERK signaling is a MAP3K inhibitor, a MAK2K inhibitor, a MAPK inhibitor, preferably an MKK7 inhibitor, an MKK4 inhibitor, an MKK3 / 6 inhibitor, an MEK1 / 2 inhibitor, a JNK inhibitor, a p38 inhibitor, a p53 inhibitor or an ERK inhibitor. Preferably, the inhibitor of p53 activation is a p53 dominant negative peptide, an ataxia telangiectasia mutated (ATM) kinase inhibitor or an ataxia telangiectasia and Rad3- related protein (ATR) inhibitor. In some embodiments, the inhibitor of p53 activation is pifithrin-α or a derivative thereof; KU-55933 or a derivative thereof; GSE56 or a variant thereof; KU-60019, BEZ235, wortmannin, CP-466722, Torin 2, CGK 733, KU-559403, AZD6738 or derivatives thereof; or an siRNA, shRNA, miRNA or antisense DNA / RNA, preferably wherein the inhibitor of p53 activation is GSE56 or a variant thereof. Preferably, the cells are cultured in the presence of GSE56 and / or of Ad5-E4orf6 / 7 protein. Preferably the engineered cells obtained from the method of the invention are collected and optionally resuspended in a freezing medium for further use. Preferably, after collection, the engineered cells are then washed and resuspended, more preferably at a concentration of 2.5-10 x 106cells / ml, in a minimum volume of freezing medium (e.g., 20 ml), and cryopreserved under vapor of liquid nitrogen in cryobags or vials. ADV-00738PTEPWO The cells can be frozen until use. Preferably the cells of the method or kit of the invention are autologous cell, i.e., cells obtained from a subject, to which the cells are meant to be reinfused, once genetically modified. The present invention is also directed to pharmaceutical formulations comprising a population of the gene edited cells, obtainable by the method of the invention, or the kit of the invention, and suitable pharmaceutically acceptable excipients. The term "pharmaceutically acceptable excipient" refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, or formulation auxiliary of any conventional type that may optionally be included in the formulations of the invention and that causes no significant adverse toxicological effects to the patient. A pharmaceutically acceptable excipient is essentially non-toxic to recipients at the employed dosages and concentrations and is compatible with other ingredients of the formulation. The number and the nature of the pharmaceutically acceptable excipients depend on the desired administration form. In a further aspect, the present invention is also directed to the kit or to the gene edited cell obtainable by the method of the invention, or the pharmaceutical formulation thereof, for use as a medicament, preferably for use in the treatment of a genetic disease that can be treated by expressing the gene product of interest in a cell (gene therapy). The present invention is then also directed to the kit or to the gene edited cell obtainable by the method of the invention, or the pharmaceutical formulation thereof, for use as medicament in gene therapy, preferably in ex vivo gene therapy. The present invention is then directed also to a method of treatment of a disease by gene editing, comprising administering to a subject in need thereof a therapeutic amount of the kit of the invention or of the gene edited cells obtained from the method of the invention, or a pharmaceutical formulation thereof. Advantageously, diseases such as inborn errors of metabolism the invention can be treated by means of the present invention, benefiting from supra-physiological transgene expression and full graft editing for maximal therapeutic benefit, and also leverage on cross-correction of diseased cells from edited blood cells. Preferred diseases to be treated include: MLD, X-ALD, lysosomal storages diseases (in particular, Gaucher, Fabry, Pompe, Niemann-Pick diseases, and mucopolysaccharidoses), inborn errors of immunity, bone marrow failure syndromes (Fanconi Anemia, Blackfan- Diamond anemia, etc.), haemoglobinopathies. Cancer gene therapies in T cells and HSPCs are other potential applications. ADV-00738PTEPWO A skilled worker would be able to determine appropriate dosage rates. The term "administered" includes delivery by viral or non-viral techniques. In preferred embodiments, the ex vivo engineered cells are administered as part of an autologous cell transplant procedure. In other preferred embodiments, the engineered cells are administered as part of an allogeneic cell transplant procedure. Preferably, the subject receiving the cells is subjected to a partial or full myeloablative conditioning regimen, before administration of the cells. Example regimens may involve non- specific, chemo- or radio-therapeutic treatments. In some embodiments, the subject has received biological myeloablative or non-myeloablative conditioning regiment (e.g. myeloablative conditioning using an antibody), before administration of the cells. It should be understood that all the possible combinations of the preferred aspects of the present invention are also described, and therefore similarly preferred. Examples of preferred embodiments of the present invention and analyses of their efficacy are provided below for illustrative and non-limiting purposes. EXAMPLES MATERIALS AND METHODS Cell culture of human HSPCs G-CSF or G-CSF + Plerixafor mPB CD34+ HSPCs were purified in house with the CliniMACS CD34 Reagent System (Miltenyi Biotec) from Mobilized Leukopak (AllCells) according to the TIGET-HPCT protocol approved by OSR Ethical Committee and following the manufacturer’s instructions. HSPCs were seeded at the concentration of 7.5 x10^5 cells ml−1 in serum-free StemSpan SFEM supplemented with 100 IU ml−1 penicillin, 100 μg ml−1 streptomycin, 2% glutamine, 300 ng ml−1 hSCF, 300 ng ml−1 hFlt3-L, 100 ng ml−1 hTPO and 10 μM 16,16- Dimethyl Prostaglandin E2 (added at the beginning of the culture), 1 μM SR1 and 35 nM UM171. Alternatively, for clinical-compliant electroporation, mPB CD34+ HSPCs were cultured in a medium optimized for expansion, which is still under evaluation for patenting and that cannot be disclosed yet. All cells were cultured in a 5% CO2 humidified atmosphere at 37 °C. Vectors ADV-00738PTEPWO AAV6 donor templates were generated from a construct containing AAV2 inverted terminal repeats, produced at the TIGEM Vector Core (in the case of AAVS1 target locus under PGK promoter) or by Genewiz Azenta (for all the other AAV6 vectors) by a triple-transfection method and purified by ultracentrifugation on a caesium chloride gradient. Design of the AAV6 donor templates carrying homologies for the target loci (all-encompassing an EGFP reporter cassette) are reported in Figure 4. Vector maps were designed with SnapGene software v.5.0.7 (from GSL Biotech, available at snapgene.com). Gene editing of human HSPCs (standard conditions) and analyses For each condition, from 2.5x10^5 to 7.5x10^5 mPB-derived HSPCs were washed with ten volumes of DPBS without Ca2+ and Mg2+ and electroporated using the P3 Primary Cell 4D- Nucleofector X Kit (Lonza) and program EO-100 after 3 days of culture. HSPCs were electroporated with RNP complex RNPs at a final concentration of 2.5μM (50 pmol gRNA, Synthego). RNP complexes were assembled by incubating at a 1:1.5 molar ratio Streptococcus pyogenes (Sp)Cas9 protein (Aldevron) with pre-annealed synthetic RNA guide (Synthego) for 10min at 25 °C, according to the manufacturer’s instructions. RNA guide used for editing AAVS1 gene targets sequence SEQ ID NO: 35. After editing HSPCs were kept in culture up to seven days after editing. Four days after electroporation HSPCs were collected to extract genomic gDNA for molecular analysis. In the case of optimized editing conditions protocol, electroporation was performed with MaxCyte electroporator (HSC-3 program). When performing HDR, donor construct was provided when HSPCs were at 1 mln / mL concentration; AAV6 donor templates were delivered to the cells 15 min after electroporation at standard MOIs of 20000 (2x104vg) in the case of standard editing conditions, 5000 (5x103vg) in the case of optimized editing conditions. When editing was performed for subsequent xenotransplantation, dominant negative form of TP53 (GSE mRNA, produced and HPLC-purified lab-grade) was added to RNP mix just before electroporation. In the case of cord blood derived HSPCs, cells were cultured in Stem Span medium with cytokine concentrations as described in previous works. Electroporation was performed with MaxCyte electroporator (program HSC-3). Colony-forming cell (CFC) assays ADV-00738PTEPWO Colony-forming cell (CFC) assays were performed 24 hrs after editing procedure by plating 400-800 cells in methylcellulose-based medium (MethoCult H4434, StemCell Technologies) supplemented with 100 IU ml−1penicillin and 100 µg ml−1streptomycin. Three technical replicates were performed for each condition. Two weeks after plating, colonies were counted. After counting, for some experimental conditions, colonies of same experimental condition were pulled together and washed from methocult through multiple centrifugation steps in ten volumes of DPBS without Ca2+and Mg2+; material was used for DNA extraction and -for HDR conditions- FACS analysis. In other experiments (i.e. long-range deletion detection) they were individually picked, under microscopic guidance. Mice All experiments and procedures involving animals were performed with the approval of the Animal Care and Use Committee of the San Raffaele Hospital and authorized by the Italian Ministry of Health and local authorities accordingly to Italian law. NSG and NBSGW female mice were held in specific pathogen-free conditions. CD34+ HSPC xenotransplantation experiments For xenotransplantation the outgrowths of 7.5 x10^5 to 1x10^6 HSPCs at the start of the culture (T0) were injected intravenously 24 hrs after editing into sublethally irradiated NSG mice (180- 200 cGy) or in NBSGW mice. Matched numbers of HSPCs were seeded at day 0 of culture for each experimental group in order to transplant in each mouse the same number of culture- initiating HSPCs. Mice were randomly distributed to each experimental group. Human CD45+ cell engraftment and the presence of edited cells were monitored by serial collection of blood (approximately every 2 to 3 weeks) from the retroorbital plexus, and, at the end of the experiment (12-16 weeks after transplantation), BM and SPL were collected for end-point analyses, including florescence-activated cell sorting (FACS) of hematopoietic lineages in some experiments. Flow cytometry Immunophenotypic analyses were performed by flow cytometry using Canto II (BD Pharmingen). Cells were stained for 15’ at 4 °C with antibodies in a final volume of 100 μl and then washed with DPBS + 2% heat-inactivated FBS. Single stained and fluorescence-minus- one-stained cells were used as controls. The Live / Dead Fixable Dead Cell Stain Kit (Thermo Fisher) or 7-aminoactinomycin D (Sigma Aldrich) were included during sample preparation ADV-00738PTEPWO according to the manufacturer’s instructions to identify dead cells. For intracellular proteins detection, cells were chemically fixed and permeabilized using eBioscience™ Intracellular Fixation & Permeabilization Buffer Set kit, according to manufacturer’s instructions. Then they were stained by incubation with the required primary antibody for 1 hour. Cells were then repeatedly washed with permeabilization buffer by centrifugation to remove unbound antibodies and analysed by flow cytometry as described above. Molecular analyses For molecular analyses, gDNA was isolated with QIAamp DNA Micro Kit (QIAGEN) according to the manufacturer’s instructions. Nuclease activity was measured using a mismatch-sensitive endonuclease T7 assay (New England Biolabs) on PCR-based amplification products of the targeted locus, as previously described. Digested DNA fragments were resolved and quantified by capillary electrophoresis on 4200 TapeStation System (Agilent) according to the manufacturer’s instructions. For HDR digital droplet PCR (ddPCR) analysis, 5–50ng of gDNA were analysed using the QX200 Droplet Digital PCR System (Bio-Rad) according to the manufacturer’s instructions. HDR ddPCR primers and probes were designed to fully cover the junction between the vector sequence and the targeted locus with a single amplicon. Human TTC5 (Bio-Rad) was used for normalization. The percentage of cells harbouring biallelic integration was calculated with the following formula: (no. of target gene+ droplets / no. of TTC5+ droplets×200) −percentage of GFP+ cells. The percentage of monoallelic integration was then calculated with the following formula: percentage of GFP+ cells−percentage of cells with biallelic integration. ddPCR for long range deletions Single colonies were manually picked under microscope guidance and DNA was extracted with Quick Extract DNA Extraction Molecular Biology Reagent buffer according to manufacturer’s instructions. Primers and probes were designed to evaluate the presence of deletions just before (at 5’) and after (at 3’) the left and right homology arms, respectively, in order to search for deletions over 500-800 bp far from the nuclease target sites. Assays were analysed with QX600 Droplet Digital PCR System (Bio-Rad). Human TELO was used for normalization. Data were analysed with QuantStudio Real-Time PCR software v.1.1 (Applied Biosystem). Gene expression analyses ADV-00738PTEPWO Total RNA was extracted using RNeasy Plus Micro Kit (QIAGEN), according to the manufacturer’s instructions and DNase treatment was performed using RNase-free DNase Set (QIAGEN). Complementary DNA was synthesized with SuperScript VILO IV cDNA Synthesis Kit (Thermo Fisher) with EzDNAse treatment. cDNA was then used for quantitative PCR (qPCR) in a Viia7 Real-time PCR thermal cycler using TaqMan Gene Expression Assays (Applied Biosystems) mapping to genes listed in Table 5. Data was analysed with QuantStudio Real-Time PCR software v.1.1 (Applied Biosystem). Relative expression of each target gene was first normalized to HPRT1 and then represented as fold changes relative to the untreated cells. Long read sequencing of target loci DNA from CFUs was extracted using the Monarch HMW DNA Extraction Kit for Cells & Blood (New England Biolabs), processed with the Ligation Sequencing Kit V14 (Oxford Nanopore), acquired on a P2 Solo R10 flow cell (Oxford Nanopore) using adaptive sampling enrichment for the target locus. Reads were base called and aligned to hg38 with dorado ver. 0.7 and classified manually. Due to limited accuracy at single base-level, reads containing indels were grouped with those mapping onto the native locus. Deletions <50 bp were classified as indels, larger ones were classified as deletions. Locus coverage was Coverage 54.5-104.5 (for coverage estimation, reads not covering the entire locus but only a vector / genome junction were counted half). The frequency of false-positive translocations (i.e. technical artifacts emerging from concatenation of DNA molecules upon nanopore sequencing) was established by long read sequencing of a single untreated (UT) CFU sample on AAVS1 locus. T cell editing Peripheral blood mononuclear cells (PBMCs) were freshly purified from whole blood using Sepmate falcons (STEM CELL technologies). T cells were isolated by immune-magnetic separation using pan T-cell isolation kit (Miltenyi Biotech) according to the manufacturer’s instructions. Cells were maintained in X-VIVOTM15 serum-free medium (Lonza Bioscience) with 0.5% HSA (Baxisalta), 1% Pen / Strep (Lonza), 100 IU / mL IL-7, and 200 IU / mL IL-15 (both from Miltenyi Biotec). After 3 days of stimulation via CD3 and CD28 (Transact by Miltenyi Biotec), 5×105–10×105T cells were washed with ten volumes of Dulbecco’s phosphate-buffered saline without Ca2+and Mg2+(DPBS, Corning) and electroporated using P3 Primary Cell 4D-Nucleofector X Kit and program DS-130 (Lonza). Cells were electroporated with RNP (50 pmols of RNAguide, 25 pg Cas9, 1:2 molar ratio) and transduced ADV-00738PTEPWO with 5×104vector genomes (vg) per cell of AAV615 min after electroporation. Cells were kept in culture for up to 10 days after editing. EXAMPLE 1 Each gene of Table 1 has been tested in vitro as candidate target gene in accordance with the method of the invention. According to the experimental design (Fig.2A) mobilized-peripheral blood HSPCs CD34+ (m- PB CD34+ HSPCs) were thawed and pre-cultured for 3 days in standard conditions (cytokine- added stem span medium, according to Schiroli et al4). On the third day after thawing (day 0), the RNP complex (candidate gRNA plus Cas9 protein) was delivered to the cell through electroporation (Lonza Nucleofector). Three guide RNAs were tested for each condition, except for UBLA4 and RPS19 for which two and four different guide RNAs were tested, respectively. The day after editing (day 1), 600 cells per condition were plated into classic methocult medium for clonogenic in vitro assay (CFA) in 3 technical replicates for each condition. 4 days after editing (day 4, at which the higher value of edited cells is presumably registered before the occurrence of any counterselection event), the percentage of indels in the bulk culture was evaluated through an enzymatic non-homologous end joining assay (T7 endonuclease assay). Results are shown in Fig.2B. 14 days after editing the absolute number of red and white colonies obtained from the CFA was counted. Results are shown in Fig.2C. For each experiment beta-2 microglobulin human (Beta2M) knock-out was used as control, since Beta2M knock out is known not to preclude the cell culture composition and clonogenic output of HSPCs in vitro (Beta2M gRNA target sequence is SEQ ID NO: 34). RPS19 gene is an autosomal gene, which is implied in the pathogenesis of Blackfan-Diamond anemia, when mutated. A proof of concept of the haploinsufficiency of this gene has been reported in literature14.4 different guide RNAs were designed targeting exons 4, 5 and 6 of this gene: the ones targeting exon 4 and the one targeting exon 5 (respectively RPS19_3 and RPS19_1 in Table 2) have displayed a good cutting efficiency (45%) and were able to impair the clonogenic output of healthy donors’ HSPCs in vitro in three biological replicates (see Figs. 2B and 2C). Essential X-linked genes are, by definition, haploinsufficient in males and, in most cases, also in females (if they don’t escape lyonization).10 different genes on chromosome X for which there is evidence of haploinsufficiency in HSPCs or for which haploinsufficiency is expected (i.e. ABCB7, AIFM1, DKC1, FLNA, HCCS, MED12, OGT, PGK1, UBLA4, UBA1) have been ADV-00738PTEPWO tested, each with three different gRNAs (except for UBLA4, tested with two gRNAs); for each of them the cutting efficiency (Fig. 2B) and the impairment of the clonogenic potential of HSPCs in culture (Fig.2C) were evaluated on three different biological replicates, 2 performed on male and 1 on female donors’ HSPCs. Among the X-linked genes, a promising candidate resulted to be Ubiquitin like modifier activating enzyme 1 (UBA1), a gene which is involved in proteasomal degradation patterns. Point mutations inducing an impairment in the cytoplasmic isoform of this gene are associated to an acquired inflammatory syndrome called VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic). When completely knocking out the function of both nuclear and cytoplasmic UBA1 isoforms with an efficient guide RNA, such as gRNA targeting the exon 3 (gRNA targeting sequence SEQ ID NO: 5 in Table 2), having 70-80% efficiency, the clonogenic output was completely impaired, both in 1 female and in 2 male HSPCs donors (Fig. 2C). Other candidate genes on the X chromosome displaying high efficiency are AIFM1, DKC1 and OGT genes, for which one gRNA per each gene was identified ((gRNAs targeting sequences 12, 16 and 27, respectively in Table 2), obtaining median % of indels in culture of 70%, 60% and 58%, respectively, and impairing significantly the clonogenic output (yellow arrows in Fig.2C). EXAMPLE 2 Five promising candidate genes (UBA1, RPS19, AIFM1, DKC1 and OGT genes) and the respective best-performing gRNAs, as assessed in Example 1, were selected to verify that the clonogenic impairment in vitro correlates with the impairment of long-term engraftment in vivo. To evaluate this, a set of identical experiments was performed (Fig.3A), in which each guide gRNA was used for in vitro editing in HSPCs, as described in Example 1, then, the day after editing, the outgrowths of same number of HSPCs at the start of the culture (i.e. T0, 750,000 per mouse5) were transplanted into 5 NSG mice per each group, 6 hours after sublethal irradiation of the mice (180 Gy). Each experiment had a mock-edited control (edited in a neutral locus, the genomic safe harbour AAVS1). Blood samples were collected from mice every two weeks starting from week 5 after transplantation. At sacrifice (week 13) blood, spleen and bone marrow were collected from each mouse. All the samples at all timepoints were evaluated for human engraftment and cell composition by FACS and for indel’s percentage on genomic DNA extracted from pellet. As for the engraftment of human cells, evaluated as the percentage of cells staining positively for the surface antigen hCD45 at FACS, as expected, there was an initial tendency to a lower ADV-00738PTEPWO engraftment at earlier timepoints (weeks 5 and 7 after editing) in the experimental groups as compared to control group, but this difference was lost at later timepoints (after week 9), when there was a plateau of human engraftment for all groups. Beyond week 9, the human engraftment (as typical for xenotransplantation into this mouse model) progressively lowered over time and at sacrifice (week 13) there were no more differences in human engraftment neither in peripheral blood, spleen and bone marrow (Fig.3B). As for the percentage of indels in the human graft, the results show a clear tendency towards a stable / slight increase in the fold of indels for the AAVS1 group and a tendency to progressive reduction in the case of the candidate genes. As for UBA1 gene (1 gRNA tested) and RPS19 gene (2 gRNAs tested), in both cases a significant reduction was observed in the % of indels over time from the input (in vitro % indels, at day 4 after editing) that were of 65%, 42% and 25% for UBA1 gRNA and for RPS19 gRNAs 1 and 3, respectively, and the final % of indels in the spleen and bone marrow at the moment of sacrifice of the mice (13 weeks after transplantation), that were for all candidate genes less than 5%, differently from what happened in the control group for which the % of indels remained more or less stable over time (20-35%). As for the other three candidate genes, AIFM1, DKC1 and OGT genes (one guide RNA tested for each gene), an analogous experiment showed a similar trend in terms of human engraftment over time (slight difference between experimental and control group at week 5 on peripheral blood, lost at later time points in blood, spleen and bone marrow, Fig. 3B). As for indels’ percentage, the tendency towards a counterselection as compared to the input in vitro was much more evident for OGT gene as compared to the other two tested genes. Indel’s fold growth, obtained when normalizing for in vitro editing efficiency, show a clear tendency towards a stable / slight increase in the fold over the in vitro sample for the AAVS1 group and a tendency to progressive reduction in the case of UBA1, RPS19 and OGT genes (Fig.3C). This is indirect evidence of the disadvantage of HSPCs bearing indels in the selected genes in terms of long-term engraftment. (This evidence is not being reflected in terms of percentage of engrafted human cells over time, because the non-edited cells are expected to quickly repopulate the bone marrow niche of the mice, evening out the differences between groups). The trend observed over time confirms counterselection in the target genes as compared to the control. These loci have therefore proven to be suitable for the negative selection approach of the invention, providing for spontaneous long-term purge out of HSPCs bearing indels in vivo. ADV-00738PTEPWO EXAMPLE 3 Knock-in cassettes have been prepared to reconstitute the haploinsufficient target gene that is knocked-out in vivo by gene editing agents, restoring the clonogenic capacity in vitro and the long-term engraftment potential in vivo of edited HSPCs, expressing at the same time a gene of interest (GOI). A knock-in cassette was prepared for reconstituting UBA1 gene (Fig. 4A) after disruption by gene editing with a gRNA targeting exon 3 of UBA1 gene (gRNA target sequence SEQ ID NO: 5); inside the homology arms (left arm SEQ ID NO: 40 and right arm SEQ ID NO: 41), the knock-in cassette (sense cassette in Fig. 4A) comprises in sequence from the 5’ end to the 3’ end: the final part of exon 3 of UBA1 gene that is 3’ of the break in the endogenous gene (codon- usage optimized, in order not to be re-cut by the guide RNA after HDR) with a splicing donor domain (SD) (SEQ ID NO: 36), and a cassette for expressing a gene of interest (GOI cassette), consisting of a strong viral promoter (Spleen Focus-Forming Virus promoter, SFFV, SEQ ID NO: 37), EGFP (SEQ ID NO: 38) mocking the gene of interest, and a bGH (Bovine Growth Hormone) polyadenylation (polyA) signal (SEQ ID NO: 39). A different form of the knock-in cassette was also designed, bearing the GOI cassette in an antisense direction as compared to the transcription of the native gene (anti-sense cassette in Fig. 4A, with polyA, GOI and promoter, respectively of SEQ ID NO: 52, 53 and 54, in antisense direction). A knock-in cassette was prepared for reconstituting RPS19 gene (Fig.4B) after disruption by gene editing with a gRNA cutting in the terminal region of RPS19 gene (gRNA targeting sequence SEQ ID NO: 1, in the final part of exon 5) e; inside the homology arms (left arm SEQ ID NO: 44 and right arm SEQ ID NO: 45), the knock-in cassette comprises in sequence from the 5’ end to the 3’ end: the final part of the RPS19 gene (end of exon 5 and coding region of exon 6, codon-usage optimized, in order not to be re-cut by the guide RNA after HDR, SEQ ID NO: 42) and the gene of interest (mocked by EGFP, SEQ ID NO: 38 , followed by a bGH polyA domain, SEQ ID NO: 39) under the control of the endogenous promoter of the RPS19 gene, after reconstitution of the same via HDR, and separated from the coding region of the RPS19 gene by a P2A domain (SEQ ID NO: 43). A further knock-in cassette was also prepared for reconstituting RPS19 gene upon targeting of exon 4 with the relative gRNA (SEQ ID NO: 3), said knock-in cassette being designed similarly to that of UBA1 locus, keeping the EGFP under the control of the SFFV promoter and recoding only the initial part of exon 4 of RPS19 gene inside the knock-in cassette (codon-usage optimized RPS19 exon 4, SEQ ID NO: 61), inside the homology arms (left arm SEQ ID NO: ADV-00738PTEPWO 62 and right arm SEQ ID NO: 63). A knock-in cassette was also prepared for reconstituting OGT gene, with a design similar to that of the knock-in cassettes for UBA1. EXAMPLE 4 HDR editing experiments were performed using the guide RNA knocking out exon 3 of UBA1 gene and the one knocking out exon 5 of RPS19 gene. For each of these two loci, AAV6 constructs were designed bearing homology arms for the regions disrupted by the respective guide RNAs. To evaluate the efficacy of these vectors in restoring the clonogenic capacity, in vitro experiments were performed with a design similar to what described above (Fig. 5A), but in this case for each guide RNA the test included: a KO only condition (called RNP), a condition in which vector was simply added without RNP delivery (called AAV6 condition) and a full HDR condition (called HDR) with the respective AAV6 used as donor template in a classical HDR platform (i.e. added 15 minutes after RNP electroporation) at the standard MOI of 20000. As a control, in the AAVS1 group, a standard PGK-GFP AAV6 was used at the same dose. In the HDR conditions, editing efficiency was assessed through FACS analysis (GFP expression within the CD90+ compartment 7 days after editing) and the clonogenic restoring capacity was evaluated both in terms of colonies’ count and in terms of GFP expression of cells pooled from colonies. For each experiment, two biological replicates were performed, one of the two with adding the so-called genetic suppressor element (GSE), an editing enhancer that works as temporary inhibitor of TP53 activation4to the electroporation mix. For UBA1 gene, the results in terms of HDR efficiency (measured as % of GFP positive cells in vitro) with both sense and anti-sense constructs were similar or slightly better than what normally observed for HDR platform in standard condition, with HDR reaching 20% of AAVS1 edited Cd90+ cells (the most primitive among HSPCs), and 30% and 35% with the sense and anti-sense UBA1 constructs, respectively. As for the number of colonies, while AAVS1 RNP and AAV6 conditions did not impair significantly the colonies’ count as compared to the untreated condition (being the only impairment in this case due to the direct toxicity of electroporation and AAV6 itself), in the case of the UBA1 conditions, the strong impairment seen in the RNP condition (<25 total colonies as compared to nearly 100 in the untreated condition), was partially rescued in the HDR conditions (45 and 40 total colonies, with sense and anti-sense constructs, respectively). As for GFP expression in colonies, while in the AAVS1 group the % of GFP positive cells remained the same to what seen in culture at day 7, as for UBA1 gene for both constructs there ADV-00738PTEPWO was an increase up to nearly 80% of GFP positive cells in colonies, implying that the HSPCs bearing the intended edit have been responsible for the formation of most of the colonies that were able to be formed (Fig.5B). As for RPS19 gene, the GFP positive Cd90+ cells in culture at day 7 were around 30% and 65% in the AAVS1 and RPS19 group, respectively. In terms of clonogenic output, in the RPS19 group there was a partial rescue in the number of colonies when comparing the RNP group (<25) with the HDR group (40). As for GFP expression, in AAVS1-edited colonies the percentage of GFP positive cells was stable as compared to the in vitro culture, while it was furtherly increased to up to 80% as compared to the Cd90+ population in culture in the RPS19 group (Fig.5 C). These results provide proof of concept of selective advantage of HDR edited cells as compared to NHEJ-edited cells in vitro. EXAMPLE 5 With the most promising candidate (UBA1), it was decided to move on with the consequent step of evaluating if the selective advantage shown in vitro for HDR edited cells was maintained in vivo. 1 million HSPCs at T0 per mouse were edited and transplanted the day after into NOD.Cg- KitW-41J Tyr + Prkdcscid Il2rgtm1Wjl / ThomJ (NBSGW) mice. Groups of treatment included: an RNP only group and a full HDR group for each locus / donor template tested (AAVS1, UBA1 sense and antisense constructs).30 NBSGW female mice (6 per group) were used, without need for irradiation prior to transplantation. Blood samples were collected from mice every 2 to 3 weeks starting from week 5 after transplantation and at sacrifice (week 13) also spleen and bone marrow have been collected (Fig.6A). Part of the cells were kept in vitro for ddPCR evaluation of HDR efficiency with a specific probe assay, that showed 4 days after editing 1.1 of average edited copy per cell in the AAVS1 HDR HSPCs and 0.4 and 0.6, respectively, in the sense and anti-sense UBA1 HDR conditions (Fig.6C). As for human engraftment, at sacrifice (always measured as % of hCD45 positive cells at FACS), in all organs examined (blood, spleen and bone marrow), the UBA1 RNP condition was the one with the lowest engraftment overall (<0.1%), confirming the engraftment impairment of UBA1-KO cells (Fig.6B). Moreover, engraftment in UBA1 HDR conditions was higher as compared to that of the control group (AAVS1 HDR condition). As for the GFP expression by ADV-00738PTEPWO FACS in human cells, despite the apparent lower editing efficiency shown in vitro by ddPCR assay (left graph, Fig.6C), the UBA1-edited GFP+ cells were significantly enriched in vivo as compared to the AAVS1 group (>80% vs 30-50%) in blood, spleen and bone marrow (Fig.6C, right graphs). This experiment provides the proof of concept for effective selection of HDR-edited cells in haploinsufficient loci, such as UBA1, upon transplantation. EXAMPLE 6 A knock-in cassette alternative to that described in figure 4B was designed for the RPS19 gene, wherein the cassette comprises a splicing donor (SD) domain (SEQ ID NO: 60) instead of the bGH polyA domain, in the aim of conserving the expression of the endogenous 3’UTR of the RPS19 gene and more faithfully recapitulate physiological gene regulation (Fig.7A). In addition, a knock-in rescue cassette was designed for the OGT gene, including from the 5’ end to the 3’ end: the final portion of exon 12 (3’ to the DSB) of OGT gene which is codon- usage optimized to avoid nuclease cutting; a splicing donor domain (SD); the cassette for expressing a gene of interest (EGFP, mocking the gene of interest), in antisense direction as compared to OGT gene, including a potent viral promoter (Spleen Focus-Forming Virus promoter, SFFV) and bGH polyadenylation domain (Fig. 7B). As a stringent control for the study and next experiments, a HDR template targeting AAVS1 safe locus was also designed, which includes a potent transgene expressing cassette (SFFV promoter, EGFP and bGH polyA, having sequences SEQ ID NO: 37, 38 and 39, respectively) in antisense direction as compared to host PPP1R12C gene; 2) left and right homology arms for the target site (500 bp and 800 bp long, as for the other constructs) have sequences SEQ ID NO: 57 and 58, respectively (Fig. 7C). EXAMPLE 7 All targeted loci and knock-in constructs were compared in vitro manipulating mobilized peripheral blood (mPB) HSPCs from healthy donors in optimized culture and expansion conditions, leveraging on clinically compliant media, cytokines and electroporation systems. All knock-in cassettes, including that targeting OGT, were able to rescue the clonogenic potential of HSPCs compared to the cognate KO conditions wherein the HDR template was not provided (Fig.8A). More specifically, while as compared to the mock condition (130 colonies), the control groups (AAVS1 KO and AAVS1 HDR), show slight reduction in the number of colonies, more evident in the HDR group (60 colonies) as compared to the KO group (80 ADV-00738PTEPWO colonies), in the case of the target loci the behaviour is the opposite. KO groups show very limited number of colonies (<10 in all three loci), while the HDR conditions partially to fully restore the clonogenic outputs (UBA1, OGT and RPS19 loci with HDR displaying from 20 to 50 colonies). This effect was even more pronounced than in Figs. 5B-C, likely due to higher cutting efficiency in clinically compliant experimental settings. To prove the survival advantage of cells bearing the knock-in cassette, the percentage of GFP expressing cells was evaluated by flow cytometry in the vitro culture, specifically in the most primitive compartment, CD90+ cells, at day 4 and 7 after editing (columns D4 and D7 in Fig. 8B) and then in the CFUs at day 14 after editing (column D14 (CFA) inf Fig.8B). In the AAVS1 group (control group), as expected, there is no evident change in the % of GFP positive (GFP+) cells going from vitro to CFUs, with stable levels of 60% of GFP+ cells. In UBA1 and OGT groups, we observed significative enrichment for GFP positive cells in the CFUs, which are nearly 100% GFP+, as compared to the vitro counterpart (40% of GFP+ cells ca); in the case of RPS19 exon 5 locus, especially with RPS19 exon 5-bGHpolyA construct, the enrichment for GFP positive cells is already evident in bulk liquid culture, from day 4 (60%) to day 7 (80%), and the level of GFP+ cells is conserved from day 7 to CFUs, reflecting probably an earlier selection mechanism for this gene compared to the others. When looking at the level of expression of the transgene (GFP) in all loci at 7 days (Fig. 8C), as expected, the GFP expression levels were much higher in the conditions with GFP under the control of SFFV promoter (AAVS1, UBA1 and OGT) as compared to the ones with no promoter (RPS19) and expressing the transgene under the control of the endogenous promoter. Comparing the SFFV bearing conditions, AAVS1 and UBA1 loci were more permissive to transgene expression compared to OGT. Then, effectiveness of the strategy with different HSPCs sources was verified in KO vs HDR conditions for AAVS1, UBA1 and OGT loci, in cord-blood derived HSPCs from a male donor. The effect of selection was even more evident than in mPB-derived ones, both in terms of % of GFP+ cells in culture and in colonies over time (Fig.8D) and in terms of rescue of colonies in the HDR-edited HSPCs in target loci as compared to KO-counterparts (Fig.8E). EXAMPLE 8 To prove that HSPC bearing the knock-in cassette can engraft and repopulate immunodeficient mice, AAVS1 HDR (with the SFFV expression cassette), OGT KO, and OGT HDR HSPCs were transplanted in mice, as reported in Fig.6A; NSG rather than NBSGW mice were used in this experiment. As expected, human engraftment for the OGT KO group was virtually absent in all ADV-00738PTEPWO examined organs (Fig. 9A). Conversely, AAVS1 and OGT HDR groups displayed sustained levels (around 30%) of chimerism (% hCD45+ cells), both in peripheral blood (PB) over time, but more evidently in the spleen (SPL) and bone marrow (BM) at endpoint, suggesting limited shrinkage of the graft due to the selection mechanism. This observation reassures in terms of graft clonality and related potential issues with the platform of the invention. Despite higher editing efficiency was reported in vitro for the AAVS1 HDR group compared to the OGT HDR group in CD90+ cells (60% vs 80% of GFP+ cells by flow cytometry analysis, 7 days after editing), a clear reversal of the situation was observed in vivo (hCD45+ cells) due to GFP+ cells enrichment in OGT HDR group (Fig. 9B): AAVS1-HDR edited GFP+ cells remained stable around 60% in peripheral blood, spleen and bone marrow, while in all three organs OGT-HDR edited GFP+ cells were nearly 100% of the final graft. A similar xenotransplantation experiment, but in NBSGW mice, was performed for RPS19 with the experimental groups shown in Figs.9 C-D. As expected, human chimerism in the RPS19 KO group was low to virtually absent in all examined organs (Fig. 9C). The engraftment capacity was apparently rescued more efficiently with the RPS19-exon 5 bGH polyA construct rather than the RPS19-exon 5 3’UTR one. Despite comparable editing efficiencies were reported in vitro (% CD90+ cells) for AAVS1 HDR group and the RPS19 HDR group (Fig.9D), an evident enrichment was found for RPS19-HDR edited-cells as compared to the AAVS1 group: AAVS1 GFP+ cells remain stable around 60% in peripheral blood, spleen and bone marrow, while in all three organs RPS19 GFP+ cells are nearly 100% of the final graft. These results, in line with the ones of Example 5 for UBA1 locus, confirm that the strategy of the invention is effective independently from the targeted locus. EXAMPLE 9 Other xenotransplantation experiments have been performed to assess the flexibility of the strategy. To rule out the possibility of lower selection efficiency for X-linked loci in female cells as compared to males due do possible escape of lyonization for some genes, the experiment described in Example 5 was repeated with same design but using HSPCs from a female donor and the HDR template in antisense orientation (Figs. 9 E-F). The results provided clear evidence that the % of GFP+ cells in UBA1 locus was higher than in AAVS1 (20%) at the endpoint starting from similar editing efficiency in vitro (75-80%). EXAMPLE 10 ADV-00738PTEPWO In a separate experiment, it was evaluated the impact of the days of pre-stimulation in culture before editing in view of preserving stemness and shortening the manufacturing process without losing selection efficacy. The experimental design (Fig. 9G) was the same as in Example 5 targeting the UBA1 locus. The “standard” condition in which HSPCs are thawed 3 days before being edited (day minus 3, D-3) was compared to shorter pre-stimulation culture conditions (days -2 and -1). All edited HSPCs were transplanted at the same day. In this experiment, both in peripheral blood over time and in bone marrow at final experimental end point, both in terms of human engraftment and in terms of % of GFP+ cells there was no significant difference between day -3 and day -2 groups, meaning that the strategy of the invention works also when anticipating at least one day the editing procedure. As for AAVS1 (control locus), SFFV-HDR construct was used; as for UBA1, the antisense HDR construct only was used. Both were used at MOI of 5000 (Fig.9H). EXAMPLE 11 Next, the three selected loci (UBA1, RPS19, OGT) have been extensively studied (i) to confirm at genomic level the efficient selection of precise HDR-edited HSPCs and purge out of genotoxic events, and (ii) to evaluate the impact of targeted integration of strong promoters- containing cassettes in the chosen loci. For the first purpose, digital droplet (dd)PCR HDR assays on in vitro samples from several biological replicates (n=5) was performed to confirm GFP expression data at genomic level (Fig.10A). Results in AAVS1 locus have been normalized for being on an autosomal chromosome to allow for easier comparation with OGT and UBA1 which are on the X-chromosome and analysed in male cells. In all conditions except the AAVS1 control, progressive increase was found from day 4 to day 7 and from liquid culture to CFU of HDR-edited cells over time. Long-read sequencing through Oxford Nanopore technology at the region of integration in colonies derived from HDR-edited HSPCs (Fig.10B) confirmed that AAVS1-edited colonies were highly heterogeneous in terms of editing outcomes with high percentage of vector concatemers, vector trapping and short-range deletion events. Conversely, the picture in the UBA1 locus was much cleaner with nearly 80% HDR and very few reads from wild type and trapping events. Finally, ddPCR assays probing for large deletion events was performed around the cut site on HSPC-derived colonies from the control (AAVS1) and the other target loci (UBA1, OGT, RPS19). In these experiments, colonies at day 14 were picked individually under microscope guidance and DNA of each colony was extracted in a 96-well plate. Each assay was designed either upstream or downstream to the integration cassette and repeated both on colonies derived ADV-00738PTEPWO from HDR-edited HSCPs and on colonies derived from mock-edited HSCPs from the same biological donor. A threshold was set based on the lowest copy number values for each assay in mock-derived colonies to call colonies bearing large deletions in the test HDR-edited group. As previously reported in Fiumara et al Nat Biotechnol 2023 and Ferrari et al Cell Stem Cell 2022, AAVS1-edited HSPCs gave rise to few colonies bearing large deletions (dots below the dotted line) (Fig.10C). Conversely, all three target loci (UBA1, OGT and RPS19) showed no colonies bearing large deletions. As for the second purpose in vitro gene expression analyses was performed on the target gene and the neighbouring ones through ddPCR on sorted GFP+ cells as compared to sorted GFP- cells (from the same sample) at the end of culture (w / in CD34+ alive cells) over the expression of a normalizer (HPRT1 gene) (Fig.10D). The expression of the evaluated gene was compared to the one in HDR-edited samples in AAVS1 locus to exclude any editing-related effects that would be present in the GFP+ compartment independently on the locus chosen for integration. In the case of UBA1 genes the differential expression of UBA1 gene itself and neighbouring genes (4 Mb) with a potentially worrying effect if overexpressed (DUSP21, SLC9A7, ELK1, PORCN, GATA1, PIM2) was evaluated. For none of these genes, the expression was higher in UBA1 sorted GFP+ cells as compared to AAVS1-HDR edited GFP+ cells. Interestingly, not even UBA1 itself seems to be overexpressed if not very mildly. In the case of RPS19 locus, gene expression of RPS19, CEACAM6, IGBP1 and POU2F2 was performed. In this case as well, no overexpression was observed for any of these genes. A mild reduction of RPS19 was observed. As for OGT locus, OGT, RAB41, FOXO4, CITED1 were evaluated, and no overexpression was observed for any of these genes. All evaluated genes are listed in Table 5. Table 5 In UBA1 region UBA1, DUSP21, SLC9A7, ELK1, PORCN, GATA1, PIM2 In RPS19region RPS19, CEACAM6, IGBP1, POU2F2 In OGT region OGT, RAB41, FOXO4, CITED1 EXAMPLE 12 Other essential and haploinsufficient genes amenable to this selection strategy have been analysed. A comprehensive pipeline was developed selecting suitable genes with the following approach: first, a subset of genes were selected from those that were consistently negatively enriched across all tested cell lines in Wang et al., 2015, including K562, Jiyoye, KBM7, and RAJI, and from those that exhibited negative enrichment in all screened cell lines in Hart et al., 2015, ADV-00738PTEPWO including GBM, RPE1, A375, HCT116, HeLa, and DLD1, identifying 829 genes. Then genes essential for HSPC stemness were selected from those in Ting et al., 2018, characterized by a >3.5-fold negative enrichment in the CD34- fraction upon CRISPR-mediated knockout. Moreover, all 848 genes located on the X chromosome were included to comprehensively evaluate their candidacy for the selection strategy of the invention. All shortlisted candidates, excluding the X chromosome candidates, were analysed using DOMINO22, a web-based tool that predicts the likelihood of a gene exhibiting autosomal dominant (AD) or autosomal recessive (AR) inheritance, based on structural, functional, and interaction features of the encoded proteins. Genes predicted to be associated with autosomal dominance by DOMINO were further refined by filtering out candidates with a mutational frequency greater than 0.1% in haematological malignancies, using data from cBioPortal23. To avoid including genes with known tumor suppressor activity, candidates annotated in TSGene24, a curated database of tumor suppressor genes, were also excluded. To further ensure relevance to HSPCs, genes with low expression across hematopoietic lineages, using BloodSpot25, were also excluded. The final layer of filtering involved HEGIAP analysis26, which prioritizes genes based on their essentiality inferred from protein function and interaction networks. HEGIAP analysis was not applied to the candidates from Ting et al., 2018, as these genes are already functionally associated with HSPC stemness rather than general essentiality, aligning with the specific context of purifying selection. A refined list of suitable genes was then obtained, which is listed in Tables 3 and 4. The results of tests on target genes of Table 3 are provided hereafter. Briefly, the tests were carried out following the same experimental model used in Fig.2A. For each condition, 0.57 million cells were electroporated with 150 pM of crRNA + 150pM of tracrRNA and 100 pM of Cas9 protein using the Lonza 4D Nucleofector system with program code EO100. Twenty-four hours post-nucleofection, the edited HSPCs were seeded for colony- forming unit (CFU) assays at a density of 400 cells / mL. After 14 days in culture, colonies were counted and classified based on their morphological characteristics. The positive and negative control targets (UBA1 and AAVS1, respectively) were delivered as RNP containing 75pM sgRNA and 50pM of Cas9. This time colonies were counted dividing them into erythroid (E), myeloid (M) and of granulocyte-macrophage origin (GM). KO in safe harbour AAVS1 locus was used as negative control (no impact on colonies, higher line in figures), while UBA1 was used as positive control (lower line in the figure). ADV-00738PTEPWO Autosomal genes DCTN2 and NUDT21- and X-linked genes GNL3L, LAS1L, NAA10, RNF113A and TSR2 showed decreased clonogenic potential (Fig. 11), confirming their suitability as target genes in the context of the present invention. EXAMPLE 13 Applicability in other cell types of the selection strategy of the invention was then assessed. Starting from whole blood of a healthy male donor, T cells were isolated and cultured for three days in activating medium before being HDR-edited with Lonza Amaxa 4 electroporator and then cultured in standard conditions up to 10 days after editing. Flow cytometry analysis and DNA extraction of genomic pellets were performed on days 1, 4, 7 and 10 after editing (Fig. 12A). For RPS19 gene, exon 4 guide was used for KO and AAV6 construct with SFFV bearing cassette in exon 4 were used. For UBA1 locus, AAV6 with antisense bearing cassette was used for HDR. As for RPS19 locus, both vitality and fold growth are recapitulating what seen in HSCPs, i.e. already from early days in culture the KO-edited T cells are suffering and displaying poor fitness, which is partially restored in the HDR-edited condition. As for UBA1 and OGT loci, the same effect is much more evident and impressive in the last days of culture (from day 7) after which vitality and growth for both loci drop dramatically in the KO-edited conditions as compared to the respective HDR-edited counterparts. The loss of KO cells behind the selection mechanism appears evident by observing fold growth and vitality data (Figs. 12 C and D). EXAMPLE 14 As proof of concept, UBA1 locus was used to integrate SFFV-ABCD1-bGHpolyA cassette (Fig.13 A), but any of the other haploinsufficient gene could be used for the purpose. The AAV6 prepared for HDR comprises in sequence, from the 5’ end to the 3’ end, inside the homology arms (left arm SEQ ID NO: 40 and right arm SEQ ID NO: 41): the final part of exon 3 of UBA1 gene that is 3’ of the break in the endogenous gene (codon-usage optimized, in order not to be re-cut by the guide RNA after HDR) with a splicing donor domain (SD) (SEQ ID NO: 36), and the cassette for expressing a gene of interest in antisense direction, said cassette consisting of the polyA, GOI and promoter, respectively of sequence SEQ ID NO: 52 (bGH poly A), SEQ ID NO: 59 (codon-optimized coding sequence of ABCD1), and SEQ ID NO: 54 (SFFV promoter). With this HDR-construct, the vitality of HSPCs in vitro (Fig.13 B), the progressive selection of HDR-edited cells in vitro measured through ddPCR (Fig.13C), and the rescue of colonies ADV-00738PTEPWO (Fig. 13D) were preserved, as with the EGFP-bearing construct. Moreover, expression levels of transgene measured by flow cytometry, through intracellular staining in case of ALP protein, were comparable between EGFP and ABCD1 expressing constructs in HDR conditions for UBA1 locus (Fig. 13E). This result is a proof of concept that therapeutic transgenes can be delivered and efficiently selected for through the method of the invention. BIBLIOGRAPHY 1. Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet 22, 216–234 (2021). 2. Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 25, 776–783 (2019). 3. Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235–240 (2014). 4. Schiroli, G. et al. Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. Cell Stem Cell 24, 551-565.e8 (2019). 5. Ferrari, S. et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol 38, 1298–1308 (2020). 6. Wang, J. et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nature Biotechnology (2015) doi:10.1038 / nbt.3408. 7. Dever, D. P. et al. CRISPR / Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature (2016) doi:10.1038 / nature20134. 8. De Ravin, S. S. et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Science Translational Medicine (2017) doi:10.1126 / scitranslmed.aah3480. 9. Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Science Translational Medicine (2017) doi:10.1126 / scitranslmed.aan0820. 10. Ferrari, S. et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 29, 1428-1444.e9 (2022). 11. Allen, F. et al. Predicting the mutations generated by repair of Cas9-induced double- strand breaks. Nat Biotechnol 37, 64–72 (2019). ADV-00738PTEPWO 12. Hanlon, K. S. et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun 10, 4439 (2019). 13. Allen, A. G. et al. A highly efficient transgene knock-in technology in clinically relevant cell types. Nat Biotechnol 42, 458–469 (2024). 14. Bhoopalan, S. V. et al. An RPS19-edited model for Diamond-Blackfan anemia reveals TP53-dependent impairment of hematopoietic stem cell activity. JCI Insight 8, (2023). 15. De Ravin, S.S., Liu, S., Sweeney, C.L. et al. Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency. Nat Commun 13, 3710 (2022). 16. Chiriaco M, Farinelli G, et al. Dual-regulated lentiviral vector for gene therapy of X- linked chronic granulomatosis. Mol Ther.22(8):1472-1483 (2014) 17. Klermund J., Rhiel M., et al. On- and off-target effects of paired CRISPR-Cas nickase in primary human cells. Mol Ther.1;32(5):1298-1310 (2024) 18. Cartier, N., Hacein-Bey-Abina, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science.326(5954), 818–823 (2009) 19. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, Sabatini DM. (2015) Identification and characterization of essential genes in the human genome. Science (80- ) 350:1096–101. 20. Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. (2015) High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell 163:1515–26. 21. Ting PY, Parker AE, Lee JS, Trussell C, Sharif O, Luna F, Federe G, Barnes SW, Walker JR, Vance J, Gao MY, Klock HE, Clarkson S, Russ C, Miraglia LJ, Cooke MP, Boitano AE, McNamara P, Lamb J, Schmedt C, Snead JL. (2018) Guide Swap enables genome-scale pooled CRISPR–Cas9 screening in human primary cells. Nat Methods 2018151115:941–6. 22. Quinodoz M, Royer-Bertrand B, Cisarova K, Di Gioia SA, Superti-Furga A, Rivolta C. (2017) DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders. Am J Hum Genet 101:623–9. 23. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. (2012) The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov 2:401–4. ADV-00738PTEPWO 24. Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. (2016) TSGene 2.0: an updated literature- based knowledgebase for tumor suppressor genes. Nucleic Acids Res 44: D1023–31. 25. Gíslason MH, Demircan GS, Prachar M, Furtwängler B, Schwaller J, Schoof EM, Porse BT, Rapin N, Bagger FO. (2024) BloodSpot 3.0: a database of gene and protein expression data in normal and malignant haematopoiesis. Nucleic Acids Res 52: D1138–42. 26. Chen H, Zhang Z, Jiang S, Li R, Li W, Zhao C, Hong H, Huang X, Li H, Bo X. (2020) New insights on human essential genes based on integrated analysis and the construction of the HEGIAP web-based platform. Brief Bioinform.21(4):1397-1410. 27. Duncan C., Bledsoe J.R., et al. Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med.391:1287-1301 (2024). 28. Ngoc Tung Tran et al., Precise CRISPR-Cas–mediated gene repair with minimal off- target and unintended on-target mutations in human hematopoietic stem cells.Sci. Adv.8, eabm9106 (2022). SEQUENCES Sequences disclosed in conjunction with the present invention are enclosed and also displayed in Table 2 (SEQ ID NO: 1-34, gRNAs target sequences), Table 3 and 4 (SEQ ID NO: 70-87, and SEQ ID NO: 88-325, gRNAs sequences), and hereafter. SEQ ID NO: 34 (Beta2M gRNA target sequence) agatagttaagtggggtaag SEQ ID NO: 35 (AAVS1 gRNA target sequence) gtcaccaatcctgtccctag SEQ ID NO: 36 (codon-usage optimized UBA1 exon 3 portion with splicing donor domain) tcccgacaattgtaag SEQ ID NO: 37 (SFFV promoter) gtaacgccattttgcaaggcatggaaaaataccaaaccaagaatagagaagttcagatcaagggcgggtacatga aaatagctaacgttgggccaaacaggatatctgcggtgagcagtttcggccccggcccggggccaagaacagatg gtcaccgcagtttcggccccggcccgaggccaagaacagatggtccccagatatggcccaaccctcagcagtttc ttaagacccatcagatgtttccaggctcccccaaggacctgaaatgaccctgcgccttatttgaattaaccaatc agcctgcttctcgcttctgttcgcgcgcttctgcttcccgagctctataaaagagctcacaacccctcactcggc gcgccagtcctccgacagactgagtcgcccggg SEQ ID NO: 38 (EGFP) atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggc cacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcacc ADV-00738PTEPWO accggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctac cccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttc ttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgag ctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaac gtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggc agcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccac tacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtg accgccgccgggatcactctcggcatggacgagctgtacaagtaa SEQ ID NO: 39 (bGH polyA) ctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactc ccactgccctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtg gggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatgg SEQ ID NO: 40 (left HA UBA1 exon 3 donor template) Ttgcaaatcagaccacctgggttcagatcttaggtctgacagctgtgttaccctgggcaagtcctcacctttctg tgcctgtcccctctttgctgtaaaatgggggtactaatacttaagtcttcccttcccccacagttgctactaaca aacagaaaaacggtacccatgtgctccagggtcacctctgacctttttttcctccagatgtccagctcgccgctg tccaagaaacgtcgcgtgtccgggcctgatccaaagccgggttctaactgctcccctgcccagtccgtgttgtcc gaagtgccctcggtgccaaccaacgtgagtgtcctctccgtggagactggcagacgaggtggtgggtgggaaagt cttttgtatcactgtctgtctatccatgctccactcctgtgtgtctccctaaacttgttcttttcctctattcct agggaatggccaagaacggcagtgaagcagacatagacgagggcctttac SEQ ID NO: 41 (right HA UBA1 exon 3 donor template) tggggccaaggccgggctgaggggtgtggaatgggacattgagaggataaggttgggtggggcaggccctgacct agagtaccccctaacctggcaggtatgtgttgggccatgaggcaatgaagcggctccagacatccagtgtcctgg tatcaggcctgcggggcctgggcgtggagatcgctaagaacatcatccttggtggggtcaaggctgttaccctac atgaccagggcactgcccagtgggctgatctttcctcccaggtacctcttcctagcacccttccccctttccccc ttcccgaggcaccactgttcccggtgccacagccatttcatctttttccctactgcacacccttacagttctacc tgcgggaggaggacatcggtaaaaaccgggccgaggtatcacagccccgcctcgctgagctcaacagctatgtgc ctgtcactgcctacactggacccctcgttgaggacttccttagtggtttccaggtatcttgggggtactacccag ccttctgcccagttttctcagagcccatctctggtttattcagtagtgttcaatattgatttaatgggtcggcct gaatgtcaggttttgtgctgggggactagagtatgcaggcagcagttagcccctggccctgccttttcttttctt ctttttttttttttgagacggagtcttgctctgtcgcccaagctagagtgcagtggcgcgatctcggctcactgc aagctacacctcctgggttcacgccattctcctgcctcagcctcccgagt SEQ ID NO: 42 (codon-usage optimized RPS19 exon 5 end and exon 6) aggtggccgccgctaacaagaagcac SEQ ID NO: 43 (furin site and P2A domain) cgggccaagcgatccggatccggagccaccaacttcagcctgctgaagcaggccggcgacgtggaggagaacccc ggcccc SEQ ID NO: 44 (left HA RPS19 exon 5 donor template) cttgaggcccggtcatcaattccccaacgaatggtcctgcatagtctgcccagcccctcaggcccctcctatcag aggcaggcaggaggggattctgcagaaaagcaaacagcacggggcctcaccccgacctctctggctgactagccc ADV-00738PTEPWO aggctccaggagggtaatttagcgactatctgctttcattagcctgctcgttaacttttcccaattgatttttcg gggcttttgatctaaatgcttgcacaaacaacaccccgtcagctcccaggggggctcccactactgcccccagct cgttagaatgcacctgactagggccctcagtgggacttggctggcggcaggtggctttttgagaagcctggctca cagccaggagggaaggggctgagaacaggacctgtgctcactggggcctgcatgacccttccctccccacagcgg ccgcaaactgacacctcagggacaaagagatctggacagaatcgccggac SEQ ID NO: 45 (right HA RPS19 exon 5 donor template with splicing donor domain) aggtaaggcctgcgtttggggtggggctgggtcccttagtcgctgcccaagcatttccaaagcccatactttgtc aggtagacttatttccttctctggagggcacagcccagggtgctggtggggtcagaggagggctgcccagagaca ggagaaaggacagtcctgtctgacttttcctgttggtgctgcttagaaatttggaggcaggctggctgtggtgtc tcacccctgtaatcccagcactttgggatgccgaggcaggcgaattatctgaggtcaggagttcaagaccattct gaccaacatggagaaaccctgtctctactaaaaatacaaaattagccgggtgtggtggcacattcctgtaatctc agctactggggaggctgaggcacaaaaatcacttgaacccgggaggtggaggctgcggtgagccaagatcatgcc attgcaccccagcctgggcaacaagagtgaaactccatctcaaaaaaaaa SEQ ID NO: 46 skip SEQ ID NO: 47 skip SEQ ID NO: 48 skip SEQ ID NO: 49 (codon-usage optimized OGT exon 12 plus SD) cactcaatgttgtacccattgagccacggatttcgcaaagcaatagcagaacgtcatgggaatttatgtctagac aaggtgtgatt SEQ ID NO: 50 (left HA OGT exon 12) cttccattcataaggtactactgtttattataatatgtgcagtttaacacctaaaatttaacttttggaaatttt ttaccatcctgctttatttattttccaggattcagggaatattccagaagccatagcttcttaccgcacggctct gaaacttaagcctgattttcctgatgcttattgtaacttggctcattgcctgcaggtaaagaataacaggccagt aattggctctcagtgttgtaatagctttttaattgttgtatgccataagaatccaagcctgactggaaatagtat ttttaataggctatctgacattactttaggccaaagacatatcaaatattaaatcctgggataggactttctgga taataacttgtttttgctttctctagattgtctgtgattggacagactatgatgagcgaatgaagaagttggtca gtattgtggctgaccagttagagaagaataggttgccttctgtgcatcct SEQ ID NO: 51 (right OGT exon 12) cttttgttttaatctttttgttgtaaactaaaacacaaatacagaaaactgtaaaaatcaaatctgtggcttaat gaacgattataaagtgaacaccacccaagtcgagaaataaaacttttgtgggccacttcagaaccccttccattg tgtcctgagtataaccccctgcacttcataagacggaatccttaactccttcacttaaacactaatgatagactg atggtacttttctttaagttgaaagccataatttttttttcttttatcttttttttcttttttttttgagacggg gtcttgctctgtcgcccaggctggagtgcagcggtgtgatcatggcttactgcagccttgacctccccgagctta ggtgatcctcccacctcagcctcctgagtagctgggactacaggcgcatgccaccacacctaattttgtgttttt tgtagagatggggttttgctatgttgcccaagctggtcttgaacctctgggctcaagtgatctgcccacctcgcc cggccaaagtgctgggattacgggtgtgagccaccgcgcctggccagccatcatgtttaatggagtgcttggtat tttgtattcacctttgagaattagagcagtacttgatcaaggattggatcaaaggttggataatagattggagtg ctaggtgtactttttttttttttttgagacatagtgtctctgtcatccagactgcagtgcagtggtgccatctca gctcattgcaacctctgtctcccaggttaaagtgatgctcgtgccttagcttcccgaggagctaggattacaggc gtgtgccaccacgcctggctaatttttgtatttttagtagagatagggctttgccatgctaggctggtctcgaaa ADV-00738PTEPWO SEQ ID NO: 52 (bGH polyA antisense) ccatagagcccaccgcatccccagcatgcctgctattgtcttcccaatcctcccccttgctgtcctgccccaccc caccccccagaatagaatgacacctactcagacaatgcgatgcaatttcctcattttattaggaaagggcagtgg gagtggcaccttccagggtcaaggaaggcacgggggaggggcaaacaacagatggctggcaactagaaggcacag SEQ ID NO: 53 (EGFP antisense) ttacttgtacagctcgtccatgccgagagtgatcccggcggcggtcacgaactccagcaggaccatgtgatcgcg cttctcgttggggtctttgctcagggcggactgggtgctcaggtagtggttgtcgggcagcagcacggggccgtc gccgatgggggtgttctgctggtagtggtcggcgagctgcacgctgccgtcctcgatgttgtggcggatcttgaa gttcaccttgatgccgttcttctgcttgtcggccatgatatagacgttgtggctgttgtagttgtactccagctt gtgccccaggatgttgccgtcctccttgaagtcgatgcccttcagctcgatgcggttcaccagggtgtcgccctc gaacttcacctcggcgcgggtcttgtagttgccgtcgtccttgaagaagatggtgcgctcctggacgtagccttc gggcatggcggacttgaagaagtcgtgctgcttcatgtggtcggggtagcggctgaagcactgcacgccgtaggt cagggtggtcacgagggtgggccagggcacgggcagcttgccggtggtgcagatgaacttcagggtcagcttgcc gtaggtggcatcgccctcgccctcgccggacacgctgaacttgtggccgtttacgtcgccgtccagctcgaccag gatgggcaccaccccggtgaacagctcctcgcccttgctcaccat SEQ ID NO: 54 (SFFV promoter antisense) cccgggcgactcagtctgtcggaggactggcgcgccgagtgaggggttgtgagctcttttatagagctcgggaag cagaagcgcgcgaacagaagcgagaagcaggctgattggttaattcaaataaggcgcagggtcatttcaggtcct tgggggagcctggaaacatctgatgggtcttaagaaactgctgagggttgggccatatctggggaccatctgttc ttggcctcgggccggggccgaaactgcggtgaccatctgttcttggccccgggccggggccgaaactgctcaccg cagatatcctgtttggcccaacgttagctattttcatgtacccgcccttgatctgaacttctctattcttggttt ggtatttttccatgccttgcaaaatggcgttac SEQ ID NO: 55 (MND promoter) ctgcatttatttagtctccagaaaaaggggggaatgaaagaccccacctgtaggtttggcaagctaggatcaagg ttaggaacagagagacagcagaatatgggccaaacaggatatctgtggtaagcagttcctgccccggctcagggc caagaacagttggaacagcagaatatgggccaaacaggatatctgtggtaagcagttcctgccccggctcagggc caagaacagatggtccccagatgcggtcccgccctcagcagtttctagagaaccatcagatgtttccagggtgcc ccaaggacctgaaatgaccctgtgccttatttgaactaaccaatcagttcgcttctcgcttctgttcgcgcgctt ctgctccccgagctcaataaaagagcccaggg SEQ ID NO: 56 (chimeric gp91phox- SP146 synthetic promoter) cagaaaaggagaagtaggagccaagatttccaaactctgtggttgccttgccaagatttccaaactctgtggttg ccttgcagaaaaggagaagtaggagaagcgacttcctctttccagaagcgacttcctctttccagaggaagaggg cggaggctcacaaggcaaccacagagtttggaaatcttggaagcgacttcctctttccagcagaaaaggagaagt aggagaagcgacttcctctttccaggtccgccctcgctagatctttattctgtttttaaattttttatttttata ttttacctttaaaacatttttgttaaaagctaagacacaaacatacacattagcctaggcccacacaaagtcagg atcattaatatcactgtcttccacctccacattttgccccactggacagtcttcaagggcactaacatgcatgaa gctgtcatctatgacagcaatgcattcttctggaataccttctgaaggacctgcctgagattcttttacagttaa cttttttataagtaggagtatactctaaaataatgattaaaagtatagtctagtaaataaatgaaccagtaacat agtcatctatttttactatcaagtactatgtaatgtacataattgtatgtgctatacttttacaactggcagctc agtaggtttgtttacaccagcattgccacaaacacatgagtaatgtgttatgctacaatgtcactagatggtagg ADV-00738PTEPWO aatttttcagcacacacacacaagtatatatattatatattatattatatattatatatatatatgtatatatat atatatatatagagagagagagagagagagagagagagagatggagtcttgctctgtcgcccaggctggggtgca atgacacaatctcggctcactgcaacctgactcccaggttcaagtgattctcctgcctcagcctcctgagtagct gggactacaggtgcccaccaccatgcccagctaatttttgtatttttagtagagacggggtttcaccatgttggc cagattggtcccaaactcctgacctcaagtgatccaccccactcagcctctcaaagtgctgggattacaggcgtg agccaccgtgcctggccaacaccattataatcttatgggaccactgtcatacatgtggttcatcattggccaaag catctgtatttatatatgtatgtttcaaattatatatatatatatatatatatatatatatgatagctatacatg aacatacacacacacatatatagacatatatagcacataaaattggcacatattaagcattttgtaaatatcaac cattacaattgttactacttttctcagcaaggctatgaatgctgttccagcctgtcaaaatcacacctgtttaat gtgttttacccagcacgaagtcatgtctagttgagtggcttaaaaattgtgatcaaatagctggttagttaaaaa gttatttcactgtgtaaaatacatcccttaaaatgcactgttatttatctcttagttgtagaaattggtttcatt ttccactatgtttaattgtgactggatcattatagaccctttttttgtagttgttgaggtttaaagatttaagtt tgttatggatgcaagcttttcagttgaccaatgattattagccaatttctgataaaagaaaaggaaaccgattgc cccagggctgctgttttcatttcctcattggaagaagaagcatagtatagaagaaaggcaaacacaacacattca acctctgccacc SEQ ID NO: 57 (left HA AAVS1) gacggggctggctactggccttatctcacaggtaaaactgacgcacggaggaacaatataaattggggactagaa aggtgaagagccaaagttagaactcaggaccaacttattctgattttgtttttccaaactgcttctcctcttggg aagtgtaaggaagctgcagcaccaggatcagtgaaacgcaccagacagccgcgtcagagcagctcaggttctggg agagggtagcgcagggtggccactgagaaccgggcaggtcacgcatcccccccttccctcccaccccctgccaag ctctccctcccaggatcctctctggctccatcgtaagcaaaccttagaggttctggcaaggagagagatggctcc aggaaatgggggtgtgtcaccagataaggaatctgcctaacaggaggtgggggttagacccaatatcaggagact aggaaggaggaggcctaaggatggggcttttctgtcaccaatcctgtccc SEQ ID NO: 58 (right HA AAVS1) tagtggccccactgtggggtggaggggacagataaaagtacccagaaccagagccacattaaccggccctgggaa tataaggtggtcccagctcggggacacaggatccctggaggcagcaaacatgctgtcctgaagtggacatagggg cccgggttggaggaagaagactagctgagctctcggacccctggaagatgccatgacagggggctggaagagcta gcacagactagagaggtaaggggggtaggggagctgcccaaatgaaaggagtgagaggtgacccgaatccacagg agaacggggtgtccaggcaaagaaagcaagaggatggagaggtggctaaagccagggagacggggtactttgggg ttgtccagaaaaacggtgatgatgcaggcctacaagaaggggaggcgggacgcaagggagacatccgtcggagaa ggccatcctaagaaacgagagatggcacaggccccagaaggagaagg SEQ ID NO: 59 (codon-optimized ABCD1 coding region) atgcctgtgctgagtagacccagaccatggcggggcaacactctgaaaagaacagccgtcctgctggccctggct gcctatggggctcacaaagtctatcctctggtgagacagtgtctggcccccgccagggggctgcaggcccccgcc ggcgaacccacccaggaggccagcggcgtggccgccgcaaaggccggaatgaatagggtgtttctgcagcgcctg ctgtggctgctgcggctgctgtttccaagggtcctgtgccgcgagactggcctgctggccctgcattctgccgcc ctggtgtctaggacctttctgagcgtgtacgtggccagactggacggaaggctggcccggtgcattgtgagaaag gacccccgggccttcggctggcagctgctccagtggctgttaattgccctgcccgccacattcgtgaatagcgcc attcgatacctggagggacagctggcactgagcttcagaagtaggctggtggcccatgcctacaggctgtacttc tctcagcagacctactatagagtgagtaacatggacgggcggctcagaaatcctgaccagagcctgaccgaggac ADV-00738PTEPWO gtggttgccttcgccgcaagtgtggcccacctgtatagtaatctgaccaaacccctgcttgatgtggctgtgacc tcctataccctgctgcgagccgctaggtcccggggagcaggcaccgcctggccctctgccatcgctgggctggtg gtgttcctgaccgctaatgtgctgagagccttcagccccaaatttggagagctggtggcagaagaggccaggaga aagggcgagctgaggtacatgcactctagagtggtggctaacagcgaggagattgccttctatggaggccatgaa gtggagctggccctgctgcagagaagctaccaggatctggcctcacagatcaacttaattctgctggagagactg tggtatgtgatgctggagcagtttctgatgaagtacgtgtggtcagccagcgggctgctgatggtggctgtgccc attatcaccgccaccggatacagcgagagcgatgcagaagccgtgaaaaaagccgccctggagaaaaaggaagag gagctcgtcagcgagcgcaccgaggcttttaccatcgctcgaaatctgctgaccgccgcagccgacgcaatcgag agaatcatgtccagctacaaggaggtgactgaactggcgggatacaccgcccgggtgcatgagatgtttcaggtg ttcgaagacgtgcagcgctgccacttcaaaaggccaagagaactggaggacgctcaggccggctctgggaccatt ggtagaagcggtgtgagagtggagggccctctgaagatccgcggacaggtggtagatgtggagcaggggatcatc tgcgagaacatcccaatcgtgactccctctggcgaggtggtggtggcctcgctgaacatcagggtggaggagggt atgcacctgctgatcaccggaccaaacggctgcggaaagtccagcctgttccggatcctgggcggcctgtggccc acttacggaggagtgctgtataagcctcccccacagagaatgttctacatcccacagcggccctacatgagcgtg gggagcctgcgcgatcaggtgatctatcccgattccgtggaggatatgcagaggaaaggctactctgagcaggac ctggaggccatcctggatgtggtgcacctgcaccatatcctgcagagagagggcgggtgggaggccatgtgtgac tggaaggacgtgctgtctggcggagagaagcagcggattggcatggcccggatgttctatcataggcccaagtac gccctgctggacgagtgtacctcagctgtgtcaatcgacgtggaaggtaagatctttcaagccgccaaagacgcc gggatcgccctgctgagtattacccatagaccaagcctgtggaaataccacacccacctgctgcagtttgacggc gaggggggatggaagtttgagaagctggactcagcagctcggttgagcctgactgaggaaaagcagaggctggag cagcagctggcgggaatccccaagatgcagagaagactccaggagctctgtcagattctgggcgaggccgtggct cctgcccacgtgccagccccttccccccaggggcccggaggactgcagggcgcctcaacctga SEQ ID NO: 60 (splicing donor domain) aggt SEQ ID NO: 61 codon-usage optimized RPS19 exon 4 with splicing acceptor domain ctgacctcttctcttcccttcacag SEQ ID NO: 62 left HA RPS19 exon 4 donor template accatgtgatggctgaaatctgggtgcttcctgcatgtgggccccggtgccatcacagtggcaggacagggcagt tcctccagagctgtgtgacacggagccagtgagtaccctctggcacctcagtttcactctttaaaggagagtagc acttgacacacctgttgagtcctcagagtaacccggccctcaggtgaagaagggtggagagatcgaaaagcattt ggcacagggcctggcagatgtgtgctccagttaatagaagcgtgcaagcgtttctggggaggctggtgtgtcgac tggattttacggagctttttttgcaggcaaggaggctggctggggtggaccagggacttgcccaagccagccttc cctgtgtctgcagaggggctggtacacattccaagcagggggcacccactgcacagagtgtctgccctgcccttg ttatcctgagctctccagactgaggtggcccggagagtggcaataggtcccttcactcctgcttctctggggccc atggagatggtcacagctaggctccacccctacataacctcaggttcaattcaacagcagtgctgctgggatagt aaccactaaagaagttggccctggagatggtgggagtgcccacccagggtgcagggctgtttgtcaaggaagagc tagccgggggggtgggtgaggagagggggctgtcagtttctgggtgttagtgtgtgttttcagtttcccttctta taaaacagtgagaattagctgtttacacacaaggaattgtttacctgaga SEQ ID NO: 63 right HA RPS19 exon 4 donor template ADV-00738PTEPWO cttccacagcgcggcacctgtacctccggggtggcgctggggttggctccatgaccaagatctatgggggacgtc agagaaacggcgtcatgcccagccacttcagccgaggctccaagagtgtggcccgccgggtcctccaagccctgg aggggctgaaaatggtggaaaaggaccaagatgggtaagcagggtagagggggctgcattgatggagtagccttg aggcccggtcatcaattccccaacgaatggtcctgcatagtctgcccagcccctcaggcccctcctatcagaggc aggcaggaggggattctgcagaaaagcaaacagcacggggcctcaccccgacctctctggctgactagcccaggc tccaggagggtaatttagcgactatctgctttcattagcctgctcgttaacttttcccaattgatttttcggggc ttttgatctaaatgcttgcacaaacaacaccccgtcagctcccaggggggctcccact

Claims

ADV-00738PTEPWO CLAIMS 1. Method for in vitro or ex vivo engineering of a cell, comprising introducing into a cell: a) a gene editing agent comprising, or consisting of: a.i) a nuclease capable of introducing a double strand break (DSB) in a target site in the cell genome; and a.ii) a guide RNA (gRNA) targeting the target site; or a gene editing agent comprising, or consisting of: a.i.1) a nickase capable of introducing a single strand break in a DNA strand of the target site, and a.ii.2) a pair of guide RNA (gRNA), each targeting the nickase to opposite strands of the target site; wherein the target site is located within a functional region of a target gene, wherein the target gene is a gene that is haploinsufficient and / or that is present in single copy in the cell; and b) a donor template that comprises: b.i) a knock-in cassette comprising an exogenous polynucleotide encoding a gene product of interest, or a portion thereof; and b.ii) homology arms (HAs) on either side of the knock-in cassette, wherein the 5' homology arm has a sequence comprising, or consisting of, a sequence that is homologous to a sequence located 5' of the DSB in the target site of the cell genome and the 3' homology arm has a sequence comprising, or consisting, of a sequence that is homologous to a sequence located 3' of the DSB in the target site of the cell genome; wherein the donor template comprises an exogenous polynucleotide having sequence capable of reconstituting the target gene upon integration of the knock-in cassette into the target site of the cell by homology-directed repair (HDR) of the DSB, and wherein integration of the knock-in cassette by HDR of the DSB results in a gene edited cell that expresses the gene product of the target gene and the gene product of interest; preferably wherein the gene product of interest is different from the gene product of the target gene.

2. Kit for in vitro or ex vivo engineering of a cell, comprising: a) a gene editing agent comprising, or consisting of:ADV-00738PTEPWO a.i) a nuclease capable of introducing a double strand break (DSB) in a target site in the cell genome; and a.ii) a guide RNA (gRNA) targeting the target site; or a gene editing agent comprising, or consisting of: a.i.1) a nickase capable of introducing a single strand break in a DNA strand of the target site, and a.ii.2) a pair of guide RNA (gRNA), each targeting the nickase to opposite strands of the target site wherein the target site is a site located within a functional region of a target gene, wherein the target gene is a gene that is haploinsufficient and / or that is present in single copy in the cell; and b) a donor template that comprises: b.i) a knock-in cassette comprising an exogenous polynucleotide encoding a gene product of interest, or a portion thereof; and b.ii) homology arms (HAs) on either side of the knock-in cassette, wherein the 5' homology arm has a sequence comprising or consisting of a sequence that is homologous to a sequence located 5' of the DSB in the target site of the cell genome and the 3' homology arm has a sequence comprising or consisting of a sequence that is homologous to a sequence located 3' of the DSB in the target site of the cell genome; wherein the donor template comprises an exogenous polynucleotide having sequence capable of reconstituting the target gene, upon integration of the knock-in cassette into the target site of the cell by homology-directed repair (HDR) of the DSB, such that integration of the knock-in cassette by HDR of the DSB results in a gene edited cell that expresses the gene product of the target gene and the gene product of interest; the kit optionally comprising c) a cell population; preferably wherein the gene product of interest is different from the gene product of the target gene.

3. The method of claim 1 or the kit of claim 2, wherein the cell is a hematopoietic stem cells (HSC), a hematopoietic stem and progenitor cells (HSPC), a T cell, a B cell, or a NK cell; preferably a human cell.ADV-00738PTEPWO 4. The method or kit of any one of claims 1-3, wherein the target gene is selected from the group consisting of: UBA1, RPS19, ABCB7, AIFM1, DKC1, FLNA, HCCS, MED12, OGT, PGK1, and UBL4A genes; preferably the cell being a HSPC.

5. The method or kit of any one of claims 1-4, wherein the target site is within an exon of UBA1 gene, RPS19 gene, or OGT gene.

6. The method or kit of any one of claims 1-5, wherein the gRNA of the gene editing agent targets a target site having sequence comprising, or consisting of, any one of sequences SEQ ID NO: 1, 3, 5 or 27.

7. The method or kit of any one of claims 1-6, wherein the gRNA of the gene editing agent targets a target site having sequence comprising, or consisting of SEQ ID NO:

5.

8. The method or kit of claim 7, wherein the knock-in cassette of the donor template comprises in sequence from the 5’ end to the 3’ end: - an exogenous polynucleotide having sequence capable of reconstituting UBA1 said sequence being SEQ ID NO: 36, - an exogenous polynucleotide encoding for a gene product of interest, under the control of an exogenous promoter, preferably of a promoter having sequence SEQ ID NO: 37, 55 or 56, and - a polyadenylation signal, preferably a bGH polyadenylation signal having sequence SEQ ID NO: 39; preferably wherein the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 40 and 41, respectively.

9. The method or kit of any one of claims 1-5, wherein the gRNA of the gene editing agent targets a target site having sequence comprising, or consisting of, SEQ ID NO:

1.

10. The method or kit of claim 9, wherein the knock-in cassette of the donor template comprises in sequence from the 5’ end to the 3’ end: - an exogenous polynucleotide having sequence capable of reconstituting RPS19 gene said sequence being sequence SEQ ID NO: 42, - a P2A domain having sequence SEQ ID NO: 43,ADV-00738PTEPWO - an exogenous polynucleotide encoding for a gene product of interest, and optionally a polyadenylation signal, preferably a bGH polyadenylation signal having sequence SEQ ID NO: 39; preferably wherein the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 44 and 45, respectively.

11. The method or kit of any one of claims 1-5, wherein the gRNA of the gene editing agent targets a target site having sequence comprising, or consisting of, SEQ ID NO:

27.

12. The method or kit of claim 11, wherein the knock-in cassette of the donor template comprises in sequence from the 5’ end to the 3’ end: - an exogenous polynucleotide having sequence capable of reconstituting OGT gene said sequence being SEQ ID NO: 49, - an exogenous polynucleotide encoding for a gene product of interest, under the control of an exogenous promoter, preferably of a promoter having sequence SEQ ID NO: 37, 55 or 56, and - a polyadenylation signal, preferably a bGH polyadenylation signal having sequence SEQ ID NO: 39; preferably wherein the left and right HAs of the donor template have sequences comprising, or consisting of, SEQ ID NO: 50 and 51, respectively.

13. The method or kit of any one of claims 1-4, wherein the target site is within an exon of a target gene selected from the group consisting of: DCTN2, EIF2S3, GNL3L, LAS1L, NAA10, NUDT21, RNF113A, and TSR2 genes.

14. The method or kit of any one of claims 1-13, wherein the exogenous polynucleotide encoding for a gene product of interest is a polynucleotide encoding ABCD1 gene product, preferably having sequence SEQ ID NO:

59.

15. The method or kit of any one of claims 1-6, 7, 9, 11, 13-14, wherein the knock-in cassette of the donor template comprises the exogenous polynucleotide encoding for the gene product of interest in antisense direction, the knock-in cassette comprising in sequence from the 5’ end to the 3’ end:ADV-00738PTEPWO - the exogenous polynucleotide having sequence capable of reconstituting the target gene, - the polyadenylation signal - the exogenous polynucleotide encoding for a gene product of interest, and - the promoter.

16. A population of gene edited cells obtained by the method of any one of claims 1-15.

17. A pharmaceutical composition comprising the kit of any one of claims 2-15, or the population of cells of claim 16, and suitable pharmaceutically acceptable excipients.

18. The kit of any one of claims 2-15, or the population of cells of claim 16, or the pharmaceutical formulation of claim 17, for use as medicament, preferably for use as medicament in gene therapy.

19. The kit of claim 14, or the population of cells of claim 16 or the pharmaceutical formulation of claim 17 when depending on claim 14, for use in a method of treatment of X-ALD.

20. The kit of claim 14, or the population of cells of claim 16 or the pharmaceutical formulation of claim 17 when depending on claim 14, for use in a method of treatment of a disease selected from: MLD, lysosomal storages diseases, inborn errors of immunity, bone marrow failure syndromes, haemoglobinopathies.

Images